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ABSTRACT AND KEYWORDS
Menstrual-toxic shock syndrome (TSS) is a serious illness that afflicts
women of pre-menopausal age worldwide, and arises from vaginal infection by
Staphylococcus aureus and concurrent production of toxic shock syndrome toxin1 (TSST-1). The aim of this study was to investigate the influence of aberrant
vaginal states and indigenous vaginal bacteria on production of TSST-1 and
identify women who are most susceptible to menstrual-TSS. A TSST-1 reporter
strain of S. aureus was grown in the presence of vaginal swab contents collected
from women in London, Ontario with healthy and aberrant vaginal states. Gene
expression assays were also conducted to monitor toxin production in response
to indigenous vaginal bacteria. This study found that Streptococcus agalactiae
significantly induces TSST-1 production, while resident Lactobacillus spp.
suppress production. Results also indicate that women with aerobic vaginitis, but
not bacterial vaginosis, may be more susceptible to menstrual-TSS and would
benefit most from prophylactic treatment.

Keywords: Menstrual-toxic shock syndrome, Staphylococcus aureus, toxic shock
syndrome toxin-1, lactobacilli, aerobic vaginitis, bacterial vaginosis,
Streptococcus agalactiae, vaginal microbiota

iii

DEDICATION

For my parents, Duncan and Elaine, and brothers, Stuart and Cameron, who
have always provided me with love and support.

ACKNOWLEDGMENTS
First and foremost I would like to thank Dr. Gregor Reid for taking me into
the lab and giving me this amazing experience. He has truly been a great mentor
and has provided me with opportunities that could not have been obtained
elsewhere. I would also like to thank Dr. Wayne Miller for giving me helpful
insights throughout my project. Thanks is also given to the entire Reid lab,
including Lesley Carmichael and Shannon Mifflin, for their day-to-day support
and friendship. I am grateful for the guidance received by my advisory committee,
Drs. John McCormick and Kelly Summers, who were always available for giving
me assistance during the course of my project. Thanks is also given to Drs.
Jingru Li and Greg Gloor for their technical assistance and willingness to help.
Finally, I would like to extend my thanks to Holly Ings and Esther Graham who
made the clinical study successful and enjoyable, as well as all the participants
who participated in the study.

TABLE OF CONTENTS
TITLE PAGE........................................................................................................... I
CERTIFICATE OF EXAMINATION....................................................................... ii
ABSTRACT AND KEYWORDS........................................................................... iii
DEDICATION........................................................................................................ iv
ACKNOWLEDGMENTS.........................................................................................v
TABLE OF CONTENTS........................................................................................vi
LIST OF FIGURES.................................................................................................x
LIST OF TABLES.................................................................................................xi
LIST OF ABBREVIATIONS................................................................................ xii
CHAPTER 1- INTRODUCTION..............................................................................1
1.1.

Focus of Thesis........................................................................................... 2

1.2.

Vagina........................................................................................................ 2

1.2.1.

Anatomy and Physiology....................................................................... 2

1.2.2.

Development........................................................................................ 3

1.2.3.

Menstrual Cycle.................................................................................... 4

1.2.4.

Immune and Host Protective Systems.....................................................6

1.2.5.

Urogenital Infections............................................................................ 11

1.3.

Menstrual-TSS.......................................................................................... 12

1.3.1.

Pathogenesis......................................................................................12

1.3.2.

TSS Subtypes.....................................................................................13

vi

14

1.3.3.

E pidem iology

1.3.4.

Treatment........................................................................................... 15

1.3.5.

Disease Progression........................................................................... 17

1.3.5.1.

Course of Infection........................................................................ 17

1.3.5.2.

S. aureus Colonization.................................................................. 19

1.3.5.3.

TSST-1 Production........................................................................21

1.3.5.4.

TSST-1 Translocation...................................................................26

1.3.6.

Antibody Titres to TSST-1....................................................................27

1.3.7.

The Tampon Hypothesis......................................................................28

1.4.

Vaginal Microbiota..................................................................................... 31

1.4.1.

Definition............................................................................................ 31

1.4.2.

Techniques used to decipher the vaginal microbiota.............................. 34

1.4.3.

Aberrant States...................................................................................36

1.4.3.1.

Bacterial Vaginosis........................................................................36

1.4.3.2.

Aerobic Vaginitis........................................................................... 39

1.5.

Rationale for studying S. aureus TSST-1 production inaberrant states...........41

1.6.

Hypothesis and Objectives..........................................................................42

CHAPTER 2- MATERIALS AND METHODS.....................................................44
2.1.

Denaturing Gradient Gel Electrophoresis.................................................... 45

2.1.1.

Clinical Samples..................................................................................45

2.1.2.

DNA Extraction and Amplification.........................................................45

2.1.3.

Denaturing Gradient Gel Electrophoresis............................................. 48

2.1.4.

DNA Re-amplification and Purification.................................................. 51

2.1.5.

Sequencing........................................................................................ 51

2.2.

Clinical Study of Vaginal Microbiota of Premenopausal Women.................... 52
vii

2.2.1.

Ethics Statement.................................................................................52

2.2.2.

Study Population and Recruitment....................................................... 52

2.2.3.

Sample Collection...............................................................................53

2.3.

Bacterial DNA Preparation for lllumina Sequencing...................................... 57

2.4.

Luminescence Assay..................................................................................58

2.5.

Supernatant Challenge Assay.................................................................... 60

2.5.1.

Bacterial Cultures and Conditions........................................................60

2.5.2.

SDS-PAGE and Western Blot...............................................................64

2.5.3.

Real-Time PCR...................................................................................67

2.6.

2.5.3.1.

S. aureus RNA Extraction..............................................................67

2.5.3.2.

Quantification of tst Expression..................................................... 71

Statistical Analysis..................................................................................... 72

CHAPTER 3- RESULTS......................................................................................73
3.1.

DGGE versus 16S rRNA Sequencing by lllumina.........................................74

3.2. Vaginal Microbiota of Pre-menopausal Women With and Without Bacterial
Vaginosis in London, ON..................................................................................... 78
3.3.

Abundance of Staphylococcus aureus in Pregnant Women in Toronto, ON ....84

3.4.

Expression of tst in S. aureus in Women With and Without Bacterial Vaginosis
87

3.5. TSST-1 Production in Response to Vaginal Bacteria Associated with Bacterial
Vaginosis, Aerobic Vaginitis and a Healthy Microbiota............................................91
CHAPTER 4- DISCUSSION................................................................................ 99
4.1.

Induction and Inhibition of TSST-1 by Vaginal Bacteria...............................100

4.2.

S. aureus TSST-1 Production in Aberrant States........................................ 106

4.3.

Prevalence of S. aureus and Other Bacteria Associated with Aberrant States
108

4.4.

Future Directions......................................................................................113

4.5.

Conclusions............................................................................................. 115

CHAPTER 5- REFERENCES.............................................................................119

v iii

Appendix 1- UWO HSREB Full Board Submission Form........................... 143
Appendix 2- Recruitment Poster.................................................................... 167
Appendix 3- Letter of Information and Consent...........................................168
Appendix 4- Study Questionnaire.................................................................. 173
Appendix 5A- Luminescence Data................................................................. 175
Appendix 5B- Growth Curves for Luminescence Assay..............................178
Appendix 6- Growth Curves of S. aureus MN8 in Response to Supernatant
Challenge.......................................................................................................... 182
Appendix 7 - Publications During Thesis..................................................... 184
Curriculum Vitae............................................................................................... 186

IX

LIST OF FIGURES
Figure 1.1. Pathogenesis of menstrual-TSS........................................................ 18
Figure 1.2. Regulation of the agr system in S. aureus.........................................24
Figure 2.1. Sample collection of clinical study in London, ON............................. 54
Figure 2.2.Vaginal swab processing of the ESwab transport system................. 59
Figure 3.1 A. DGGE analysis of subjects of healthy and intermediate status.....75
Figure 3.1B. DGGE analysis of subjects of intermediate and BV status............. 76
Figure 3.2. Comparison of DGGE and sequencing by lllumina.......................... 77
Figure 3.3A. Vaginal smear of healthy subject from London, O N....................... 79
Figure 3.3B. Vaginal smear of intermediate subject from London, ON............... 80
Figure 3.3C. Vaginal smear of subject with BV from London, O N ...................... 81
Figure 3.4. Vaginal microbiota of subjects recruited from London, ON............... 83
Figure 3.5A. Vaginal microbiota of subjects recruited from Toronto, ON.............85
Figure 3.5B. Abundance of Staphylococcus spp. in clinical samples.................. 86
Figure 3.6A. Expression of tst in response to vaginal clinical samples............... 88
Figure 3.6B. Sustained tst expression in response to clinical samples............... 89
Figure 3.6C. Sustained tst expression in response to clinical samples.............. 90
Figure 3.7. Production of TSST-1 in response to vaginal isolates..................... 92
Figure 3.8A. Expression of tst in response to lactobacilli................................... 94
Figure 3.8B. Expression of tst in response to AV-associated bacteria............... 95
Figure 3.8C. Expression of tst in response to BV-associated bacteria............... 96
Figure 3.9. Total protein expression of bacteria used to challenge S. aureus.... 98
Figure 4.1. TSST-1 production by S. aureus in AV environment..................... 117

LIST OF TABLES

Table 2.1. PCR Master Mix for DGGE................................................................ 47
Table 2.2. Composition of dénaturant solutions used for DGGE........................ 49
Table 2.3. Nugent score criteria for BV diagnosis...............................................56
Table 2.4. Bacterial strains used for supernatant challenge assay.....................62
Table 2.5. Grouping of bacteria for supernatant challenge assay...................... 63
Table 2.6. Composition of polyacrylamide gels for SDS-PAGE......................... 66
Table 2.7. Master Mix components for MultiScribe Reverse-Transcription........ 70

XI

LIST OF ABBREVIATIONS
a8

alternative sigma-factor B

agr

accessory gene regulator locus

AHL

acylated homoserine lactones

Al

auto-inducers

AIP

auto-inducing peptides

APC

antigen-presenting cell

AV

aerobic vaginitis

BCA

bicinchoninic acid

BHI

brain heart infusion media

BV

bacterial vaginosis

CcpA

catabolite protein A

CDC

Centers for Disease Control and Prevention

CPS

capsular polysaccharide

ere

catabolite-responsive elements

DAB

diaminobenzidine

DGGE

denaturing gradient gel electrophoresis

DPD

4,5-dihydro-2,3-pentanedione

ECM

extracellular matrix

EPS

extracellular polymeric substance

FDA

food and drug administration

FnBP

fibronectin-binding protein

FSH

follicle-stimulating hormone

xn

GAS

group A Streptococcus

GBS

group B Streptococcus

HCMV

human cytomegalovirus

HIV

human immunodeficiency virus

HPLC

high-performance liquid chromatography

HPV

human papilloma virus

HRT

hormone replacement therapy

HSV

herpes simplex virus

ica

intercellular adhesion locus

IFN

interferon

IgA

immunoglobulin A

IL

interleukin

IVIG

intravenous immunoglobulin

LAB

lactic acid bacteria

LH

luteinizing hormone

LPS

lipopolysaccharide

LTA

lipoteichoic acid

M-CSF

macrophage colony-stimulating factor

MHC

major histocompatibility complex

MMP

metalloproteases

MRS

de Man, Rogosa and Sharpe media

MRSA

methicillin-resistant Staphylococcus aureus

MSCRAMM

microbial surface components recognizing adhesive
matrix molecules

PAMP

pathogen-associated molecular pattern

PCR

polymerase chain reaction
xi ii

PEC

pyrogenic exotoxin type C

PRR

pattern recognition receptor

PTB

preterm birth

QS

quorum sensing

RAP

RNAIII-activating protein

RFLP

restriction fragment length polymorphism

RIP

RNAIII-inhibiting protein

Rot

repressor of toxins

SAG

superantigen

SDS-PAGE

sodium dodecyl sulfate polyacrylamide gel electrophoresis

SE

staphylococcal enterotoxin

SLPI

secretory leukocyte peptidase inhibitor

STI

sexually-transmitted infection

TCA

trichloroacetic acid

TCR

T-cell receptor

TCRS

two-component regulatory system

TEMED

N,N, A/^A/Metramethylethylenediamine

TGF

transforming growth factor

TLR

toll-like receptor

TNF

tumor necrosis factor

TSS

toxic shock syndrome

TSST-1

toxic shock syndrome toxin-1

VDMP

vaginally-defined medium + 0.5% proteose peptone

WC

vulvovaginal candidiasis

XIV

CHAPTER 1

INTRODUCTION
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1.1. Focus of Thesis

The purpose of this study is to investigate the relationship between the
vaginal microbiota and Staphylococcus aureus in the context of menstrual-Toxic
Shock Syndrome (TSS). This section will cover information on the site of
infection, as well as the nature of S. aureus and key information that has yet to
be uncovered. In order to appreciate the dynamic nature of menstrual-TSS,
including its pathogenesis and associated risk factors, it is important to first
consider the physiology of the vagina.
1.2. Vagina

1.2.1. Anatomy and Physiology

The female genital tract is a system of several structures that function
together in reproduction. The tract as a whole consists of the ovaries, fallopian
tubes, uterus, vagina and vulva. The vagina in particular is important as it is
exposed to the external environment and is thus vulnerable to invasion by
external agents such as bacteria, viruses and fungi. The vagina is an elastic
muscular canal with a length of approximately 7-9 cm that extends from the
cervix to the external vulva. The vaginal wall is lined with a non-keratinized
stratified squamous epithelium attached to underlying stromal cells and a
basement membrane. The vaginal wall lacks glands and thus does not produce
mucus, which instead comes from the cervical mucosa and transudate through
the vaginal epithelium (Paavonen, 1983). Glycogen is present in the middle and
superficial layers of the epithelium and is dependent upon the amount of
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circulating estrogen, and thus fluctuates throughout the menstrual cycle. During
mid-cycle, the vagina is under anaerobic conditions relative to atmospheric gas
levels; oxygen is at a partial pressure of 3 mm Hg (versus 100-140 mm Hg
atmospheric) and carbon dioxide at 64 mm Hg (versus 5 mm Hg atmospheric)
(Wagner et al., 1984). The nature of the vagina makes it a unique habitat for
microorganisms.
1.2.2. Development

The vagina of a newborn is influenced by estrogen from the mother, and
includes a stratified squamous epithelium high in glycogen content, as well as the
presence of lactic-acid-producing bacteria and an acidic pH. In early childhood,
however, the effects from maternal hormones are lost and there is a thinning of
the vaginal epithelial layer, loss of glycogen and subsequent neutral pH and a
reduced population of lactic-acid-producing bacteria (Gerstner et al., 1982; Hill et
al., 1995). The event of puberty, typically occurring from the age of 8-13 years,
initiates changes in the vagina due to increased circulation of adrenal and
gonadal hormones, including estrogen (Farage & Maibach, 2011). Menarche, the
first menses experienced in an individual, typically begins at the age of 12-13
years, and it takes around six years to establish regular menstrual cycles with
predictable occurrences of menses (Flug et al., 1984; WHO 1986; BoyntonJarrett et al., 2011). Following puberty, the vaginal wall again begins to thicken
through the proliferation of stratified squamous epithelial cells, which results in
increased glycogen content in response to elevated estrogen levels
(Hammerschlag et al., 1978). In particular, circulating estrogen triggers
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underlying stromal cells to release soluble factors to the neighboring epithelial
cells and induce cellular changes (Cunha & Young, 1992). Glycogen deposits in
the vaginal epithelium and is metabolised anaerobically primarily by lactic-acid
bacteria (LAB), and to a lesser degree by vaginal epithelial cells (Boskey et al.,
2001). Metabolism of glycogen leads to lactic acid production through
fermentation of glucose which lowers the pH of the vagina. Several investigators
over the years have reported varying pH values for the healthy vagina, but it
tends to range from about 3.5 to 5.0 (Owen & Katz, 1999). At the onset of
menopause comes a drop in estrogen levels, which causes a thinning of the
vaginal epithelium, loss of glycogen content and subsequent loss of lactobacilli.
This in turn leads to an increased pH from 4.5 to about 6.0 (Roy et al., 2004).
This effect has been shown to be reversible by hormone replacement therapy
(HRT) (Heinemann & Reid, 2005).
1.2.3. Menstrual Cycle

The human menstrual cycle consists of a series of events dictated by
fluctuating hormone levels. The cycle can be broken down into three phases: the
follicular phase (or proliferative phase), ovulation and the luteal phase (or
secretory phase). The follicular phase typically marks days 1-13 of the cycle, and
is characterized by a rise in follicular-stimulating hormone (FSH), released by the
anterior pituitary gland. FSH stimulates development of ovarian follicles, which in
turn begin to secrete estradiol. As this phase progresses, elevated estradiol
suppresses FSH production, leading to the atrophy of all but the most dominant
follicle, subsequently referred to as the tertiary follicle. Estradiol also contributes
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to endometrial remodeling and proliferation of the uteral wall at this time, as well
as revascularization of the tissue. Initial triggering of this event seems to be
independent of estradiol and is still not fully understood (Lecce et al., 2001;
Maybin & Critchley, 2011), but recent studies have shown that progesterone
withdrawal that occurs at the end of the luteal phase seems to trigger repairassociated molecules such as fibronectin (Cao et al., 2007). Ovulation occurs
when levels of estradiol reach a threshold that triggers a surge in luteinizing
hormone (LH), an event which in turn triggers the release of the ovum from the
tertiary follicle. This phase typically occurs from day 13-16 of the cycle, and the
LH surge can last for 48 hours. The luteal phase typically marks day 16-28 of the
cycle, and is marked by increased production of progesterone from the corpus
luteum, an endocrine structure that remains following the rupture of the tertiary
follicle. Progesterone, together with estradiol, is responsible for the thickening of
the uteral endometrium in preparation of embryo implantation; in particular, a
network of reticular fibers containing type III and type I collagen is built up in the
extracellular matrix (ECM) of the endometrium. The proliferation of the surface
endometrial cells is dependent upon hormonal stimulation of the underlying
stromal cells (Cunha & Young, 1992).
Progesterone also triggers release of estradiols from the adrenal glands,
both of which suppress LH and FSH. If fertilization of the ovum does not occur,
the corpus luteum atrophies and progesterone and estradiol levels drop, leading
to menstruation. This event marks day 1 of the cycle, and results in sloughing of
the uteral endometrium and blood flow through the vaginal canal that typically
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lasts for 3-5 days. Breakdown of the endometrial extracellular matrix occurs
through activity of matrix metalloproteases (MMPs), which are produced by
endometrial cells and leukocytes in response to a drop in progesterone (Marbaix
et al., 1996; Salamonsen et al., 1997). Several in vitro studies have also
demonstrated an involvement of an inflammatory process in the upregulation of
MMPs during menses, including production of transforming growth factor (TGF)P, tumor necrosis factor (TNF)- a, interleukin (IL)-1, and other inflammatory
markers (Chegini et al., 1992; Hunt etal., 1992; Kauma et al., 1990; Salamonsen
& Woolley, 1998). Some of these pro-inflammatory molecules are suppressed by
progesterone, and thus shedding of the endometrium seems to result from MMP
production both by a loss of direct suppression by progesterone, as well as by a
subsequent trigger of a pro-inflammatory process (Hunt et al., 1997). It is during
the menses phase that organisms such as S. aureus can potentially cause
problems for the host, as will be discussed below.
1.2.4. Immune and Host Protective Systems

The vagina is continuously exposed to a complex community of bacteria,
some of which can be pathogenic, and so it utilizes the innate and adaptive
immune systems to help prevent infection. A critical component in innate immune
defense is the group of transmembrane signaling proteins referred to as Toll-like
receptors (TLRs) present on the epithelial cells in both the upper and lower
female genital tract (Nasu & Narahara, 2010). TLRs are part of the patternrecognition receptor (PRR) family on antigen-presenting cells (APCs) and
epithelial cells that recognize distinct molecular patterns on the surface of
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microbial cells called pathogen-associated molecular patterns (PAMPs) and
trigger a subsequent inflammatory reaction to neutralize the recognized
pathogen. The TLR family is made up often currently identified members that are
collectively able to recognize bacteria, viruses, fungi and protozoa. The binding
of a TLR to its ligand triggers a signaling transduction pathway which ultimately
activates the NF-kB pathway and expression of genes encoding pro-inflammatory
cytokines and co-stimulatory molecules in APCs and epithelial cells (McGowin et
al., 2009). One study investigated the presence of these receptors in the female
genital tract and found TLRs 1-9 to be expressed in the vaginal epithelial cells,
with TLR-2, -3, -5 and -6 being the most abundantly expressed (Herbst-Kralovetz
et al., 2008). These TLRs were also shown to respond to their respective
bacterial and viral PAMPs which elicited strong cytokine responses. The
presence of these receptors is especially apparent during times of microbial
invasion of pathogenic bacteria. For instance, a study looked at cytokine levels in
the lower genital tract of healthy women versus women with bacterial vaginosis
(BV), a condition characterised by depletion of protective lactobacilli and an
abundance of pathogenic anaerobes (Mattsby-Baltzer et al., 1998). This study
found elevated levels of the pro-inflammatory cytokine IL-1p and IL-6 associated
with BV, and linked this to the presence of endotoxins characteristic of Gram
negative bacteria. These endotoxins would be detected in large part by TLR-4,
leading to the production of these cytokines.
The vaginal epithelial cells play an important role as a physical barrier to
the intrusion of bacteria, but studies indicate that they also play an active role in
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vaginal immunity. One study investigated immunological markers from the
immortalized VK2 vaginal cell line and found that these cells produced a vast
array of cytokines, chemokines, and surface receptors (Fichorova & Anderson,
1999). This cell line constitutively expressed macrophage colony-stimulating
factor (M-CSF) (development of macrophages and neutralizing intracellular viral
infection), transforming growth factor beta 1 (TGF-(3) (development of T-cells), IL8 (attracts neutrophils), and secretory leukoproteinase inhibitor (SLPI) (an anti
microbial and anti-protease peptide). These cells can also be stimulated by IFN-y
and TNF-a to produce IL-6 (pro- and anti-inflammatory cytokine), CCL5
(recruitment of leukocytes) and the expression of major histocompatibility
complex (MHC) class II antigens. Vaginal epithelial cells are also able to secrete
elafin, a serine protease inhibitor with demonstrated antimicrobial activity against
S. aureus (Simpson et al., 1999) as well as protection against HIV infection
(Ghosh et al., 2010). Thus, vaginal epithelial cells can actively contribute to an
inflammatory response by detecting pathogens with such receptors as TLRs and
MFIC class II antigens, and response with a number of different cytokines,
chemokines and other anti-microbial agents.
Endogenous members of the vaginal microbiota are able to interact with,
and stimulate, TLRs which can elicit the release of inflammatory markers to
combat pathogenic microorganisms. One study found that stimulation of TLR-2
with lipoteichoic acid (LTA), a major component of the cell wall of Gram-positive
bacteria, and stimulation of TLR-4 with lipopolysaccharide (LPS), found in the
outer-membrane of Gram-negative bacteria, leads to production of IL-8 and
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interferon (IFN)-(3 and protects against human cytomegalovirus (HCMV) infection
(Harwani et al., 2007). In this way, endogenous bacteria of the vagina maintain a
state of immunological alertness which helps protect against invading pathogens.
Another key feature of vaginal immunity is the presence of immunoglobulin
A (IgA), a component of mucosal immunity in general (Woof & Kerr, 2006). IgAproducing plasma cells, producing both lgA1 and lgA2 isotypes, have been found
in the sub-epithelial layer of female genital tissue, including the vagina (Kutteh &
Mestecky, 1994), and indigenous bacteria appear necessary for the production of
these immunoglobulins (Benveniste etal., 1971; Moreau et al., 1978). Functions
of IgA are vast and include neutralization of pathogenic bacteria and exotoxins,
as well as prevention of mucosal penetration of indigenous bacteria into the
basolateral side of the mucosal epithelial layer (Johansen et al., 1999; Lycke et
al., 1987).
An important aspect of the vaginal microbiota is its ability to persist without
inducing a prolonged pro-inflammatory response. Various mechanisms of
mucosal immune tolerance to indigenous bacteria have been uncovered, and two
prominent theories have been established (Sansonetti, 2011). The first theory
suggests that modifications of PAMPs on commensal bacteria exist to prevent or
even antagonize interaction with host cell PRRs. For instance, the lipid A
component of LPS of Porphyromonas gingivalis, a member of the oral microbiota,
has been shown to antagonize TLR-4 due to its tetra-acylated structure, thus
preventing release of pro-inflammatory cytokines upon interaction with the host
cells (Zhang et al., 2008). In contrast, TLR-4 recognizes hexacylated lipid A
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structures and, upon recognition of this PAMP, elicits pro-inflammatory cytokines
(Takahashi et al., 1987). The classes a- and z-Proteobacteriaceae, which include
the commensal Helicobacter, have flagellin with an altered amino acid sequence
in the TLR-5 recognition site, which prevents host recognition and an
inflammatory response (Andersen-Nissen et al., 2005).
The second theory of immune tolerance to commensal bacteria is that
some of these bacteria release effector molecules that either directly suppress
pro-inflammatory or induce anti-inflammatory signals. A study found that the
supernatant of L. rhamnosus GR-1, a probiotic strain frequently used for
improving vaginal health, was capable of dampening the pro-inflammatory
response of TLR-4 stimulated with LPS (Yeganegi et al., 2009). Specifically, the
supernatant suppressed TNF-a and increased IL-10, an anti-inflammatory
cytokine. Another study found that L. casei is able to dampen the pro
inflammatory response to Shigella flexneri by way of stabilizing I-kBo, an inhibitor
of NF-kB (Tien et al., 2006). Much research has also been conducted on immune
effects induced by bacteria in the gut, which is where most vaginal bacteria
originate. Bacteroides thetaiotaomicron, a gut commensal, is able to antagonize
NF-kB through a unique mechanism in which it triggers the nuclear export of
RelA, a subunit necessary for proper activity of NF-kB (Kelly et al., 2004).
Another species of this genus and of the gut commensal population, B. fragilis,
has been shown to suppress pro-inflammatory IL-17 and trigger IL-10 release
from CD4+ T-cells, which neutralizes the inflammatory response from
Helicobacter hepaticus (Mazmanian et al., 2008). Therefore, a prominent theory

11

of immune tolerance to commensal bacteria is that many members suppress
inflammatory responses thereby counteracting pro-inflammatory stimulation by
other members, leading to an immunologically homeostatic environment at the
mucosa.
1.2.5. Urogenital Infections

Despite the protective barriers present in the vagina, opportunities arise in
which exogenous microorganisms enter the vagina and cause an infection.
These include sexually-transmitted infections (STIs) caused by bacteria
(Chlamydia trachomatis, Neisseria gonorrhoeae, and Treponema pallidum) (Biro
et ai, 1995) and viruses, as well as fungal infections and some associated with
parasites and protozoa. Vulvovaginal candidiasis (WC), referred to clinically as
common yeast infection, occurs most often through infection with the fungus
Candida albicans. Viruses known to enter the vagina and cause disease include
herpes simplex virus (HSV), human immunodeficiency virus (HIV) and human
papilloma virus (HPV). A protozoan known to infect the vagina is Trichomonas
vaginalis, causing trichomoniasis (Graves & Gardner, 1993).
Not all infections originating in the vagina are linked to sexual activity.
Some arise at opportunistic times, such as during menses when blood levels are
high or in mid-cycle when estrogen levels peak. A main reason for this is due to a
change in the composition and abundance profiles of the vaginal microbiota,
such as following exposure to antibiotics and spermicides.
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It is not clear if Staphylococcus aureus take advantage of a disrupted or
aberrant microbiota to multiply and cause menstrual-toxic shock syndrome
(TSS). This disease remains a concern in today’s society, yet there is still no
means to predict its onset. If the risk of menstrual-TSS could be associated with
a diagnosable change in the vaginal microbiota, such as onset of bacterial
vaginosis (BV) or aerobic vaginitis (AV), this would potentially provide a method
of early detection and intervention.
1.3. Menstrual-TSS

1.3.1. Pathogenesis

Toxic shock syndrome (TSS) is a systemic illness characterized by
extensive T-cell proliferation throughout the body. The condition arises from
bacterial infection and subsequent release of exotoxins known as superantigens
(SAGs). These SAGs are unique in that they bind directly to the [3-chain variable
region of the T-cell antigen receptor (TCR) (Gascoigne & Ames, 1991), as well as
the a-chain and sometimes (3-chain of MHC class II molecules of antigen
presenting cells (APCs) (Jardetzky et al., 1994; Li et al., 1999). This makes them
potent activators of CD4+ and CD8+T-cells as well as APCs (Fleischer &
Schrezenmeier, 1988; White et al., 1989). These toxins bypass the need for
APCs to process and present antigen peptides to T-cells, resulting in excessive
production and release of pro-inflammatory cytokines into the bloodstream namely IFN-y, IL-1, IL-2, TNF-a and TNF-|3 (Fast et al., 1989; Hackett & Stevens,
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1993; Ikejima et al., 1984). This, in turn, can lead to hypotension, rash formation,
multiple organ failure, shock and death.
1.3.2. TSS Subtypes

TSS has traditionally been associated with infection by Staphylococcus
aureus, but cases have been reported since 1987 due to Streptococcus
pyogenes (also known as group A Streptococcus, GAS) (Cone et al., 1987;
Stevens et al., 1989). There are two groupings of TSS: staphylococcal TSS and
streptococcal TSS. Staphylococcal TSS can be further broken down into two
subtypes: menstrual- and non-menstrual -TSS. Menstrual-TSS is a unique form
characterized by S. aureus infection in the vagina, which typically occurs around
the time of menses. Non-menstrual-TSS, on the other hand, occurs in both men
and women of any age, and can arise from various forms of S. aureus infection,
including after surgical complications (Bartlett et al., 1982), burn wounds (Bacha
et al., 1994), recalcitrant erythematous desquamating syndrome (Cone et al.,
1992) and influenza (MacDonald et al., 1987). Approximately half of all cases of
non-menstrual-TSS are caused by the SAG toxic shock syndrome toxin-1 (TSST1), with the remainder mostly due to staphylococcal enterotoxins (SEs) B and C
(Bohach et al., 1990). Menstrual-TSS, however, is predominantly associated with
TSST-1 as it is the only SAG capable of crossing the vaginal epithelium into the
bloodstream (Schlievert et al., 2000), a key step in the pathogenesis of this
condition. TSST-1, encoded by the tst gene, was first identified in 1981 by two
unrelated groups of researchers, and was initially given the names SEF (Bergdoll
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et al., 1981) and pyrogenic exotoxin type C (PEC) (Schlievert et al., 1981) before
an agreement was made to coin the name TSST-1.
1.3.3. Epidemiology

The incidence of menstrual-TSS has been routinely monitored in the
United States, but is largely unknown in other parts of the world. Monitoring of
this condition started in 1980 when a spike in TSS cases was seen, and was
strongly linked to menstruating women using tampons, in particular a newlyintroduced Rely® high-absorbency tampon from Procter & Gamble (Reingold et
al., 1982; Schlech et al., 1982). In 1980, the incidence of menstrual-TSS was
found to be 6-12 per 100,000 premenopausal women, with a higher incidence
occurring in women younger than 30 years of age (Davis et al., 1980; Latham et
al., 1982). By 1986, the incidence of menstrual-TSS decreased to 1.05 per
100,000 women in the age range of 15-44 years and 1.52 per 100,000 women in
the age range of 15-19 years, as determined through the surveillance of 6 states
in America (Gaventa et al., 1989). This drop followed removal of highly absorbent
tampons from the market. Menstrual-TSS cases accounted for 91% of all TSS
cases in 1970-80, and declined to 71% during 1981-1986 and 59% during 1987
1996 (Hajjeh et al., 1999). Since 2000, rates of menstrual-TSS have been harder
to gauge, but the number of cases for non-streptococcal TSS, a portion of which
would include menstrual-TSS, has fallen up to 2009, as reported by the Centers
for Disease Control and Prevention (CDC): the cases in 1984 numbered 482,
declining to 192 by 1994, 95 in 2004 and 74 in 2009 (CDC, 2011). The reasons
for this drop in occurrence include removal of highly absorbent tampons from the

15
market, as well as a better awareness for the condition and the requirement for
standardized labeling by the U.S. Food and Drug Administration (FDA) on
tampon products. Approximately 70% of women in North America and Western
Europe use tampons regularly (Shands eta!., 1980), so although the incidence of
menstrual-TSS is decreasing, there is much interest in better understanding this
condition and preventing its recurrence.
1.3.4. Treatment

Treatment of TSS in general tends to include antibiotics and treatment of
symptoms, and cessation of tampon use in the case of menstrual-TSS.
Investigators discovered that clindamycin, despite being a bacteriostatic antibiotic
to S. aureus, was able to significantly suppress exotoxin production in this
organism, thus serving as an effective candidate in the treatment of
staphylococcal-TSS (Dickgiesser & Wallach, 1987; Schlievert & Kelly, 1984).
However, a source for concern was this antibiotic’s failure to reduce bacterial
levels in an infection of high bacterial load. A combination of flucloxacillin, a
bactericidal (3-lactam antibiotic, with gentamicin, a protein synthesis-inhibiting
aminoglycoside antibiotic, was tested for reduction in TSST-1 production by S.
aureus (van Langevelde et al., 1997). It was discovered that flucloxacillin, both
alone and in combination with gentamicin, reduced TSST-1 production similarly
to clindamycin at logarithmic phase (approximately 95%) but less so at stationary
phase (30% and 75%, respectively). Thus, this antibiotic combination provides a
valuable alternative to clindamycin if reducing bacterial numbers in the patient is
of high priority. In more recent times, the treatment of staphylococcal-TSS has
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included the combination of clindamycin with bactericidal antibiotics such as
vancomycin.
Linezolid, the first commercially-approved drug of the oxazolidinone family
of antibiotics, has recently been of interest for treating patients suffering from
TSS. This family of antibiotics is bactericidal towards Gram-positive bacteria,
including methicillin-resistant S. aureus (MRSA), and acts by inhibiting protein
synthesis. The method of protein synthesis inhibition is unique in that it binds to
the 23S rRNA portion of the 50S subunit of the ribosome, preventing formation of
the initiation complex, making it particularly effective towards bacteria with
resistance to other families of antibiotics (Colca et al., 2003). Two groups studied
the effect of linezolid on S. aureus exotoxin production, and found the drug to be
effective in significantly reducing production of toxins such as SEA, SEB, protein
A, autolysin and hemolysins, while also decreasing growth in a dose-dependent
manner (Bernardo et al., 2004; Gemmell & Ford, 2002). Another group recently
isolated a TSST-1-producing strain of S. aureus from a patient suffering from
staphylococcal-TSS and found that TSST-1 production was completely
suppressed in vitro by linezolid and clindamycin (Stevens et al., 2006). In today’s
clinical setting, antibiotics that are currently used for the treatment of TSS
(including menstrual-TSS) include clindamycin and linezolid, and occasionally
vancomycin, daptomycin, dalbavancin and tigecycline which are all generally
effective against Gram-positive bacteria unless resistance has been developed.
Pooled intravenous immunoglobulin G (IVIG) containing antibodies to
several of the staphylococcal SAGs, including TSST-1, significantly inhibited
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human peripheral blood T-cell activation by these toxins through interfering with
SAG binding to the T-cells (Takei et al., 1993). Despite this in vitro evidence,
there are no case-control studies to measure its effectiveness in patients.
Nevertheless, some physicians implement IVIG in the treatment regime for
staphylococcal TSS (Schlievert, 2001). Case-control studies have been
conducted for IVIG usage in the treatment of patients suffering from
streptococcal-TSS, with one showing a significant improvement in 30-day
survival, as well as a reduced T-cell production of IL-6 and TNF-a (Kaul et al.,
1999). Many physicians are therefore implementing both antibiotic treatment as
well as IVIG to try and neutralize the pro-inflammatory effects of the SAGs in the
bloodstream.
1.3.5. Disease Progression

1.3.5.1.

Course of Infection

In order for menstrual-TSS to occur, three fundamental steps must take
place: (1) a strain of S. aureus must colonize the vaginal tract, (2) the strain must
produce TSST-1, and (3) the TSST-1 must be able to penetrate or translocate
across the vaginal epithelial wall into the blood (Figure 1.1).
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Figure 1.1. Simplified depiction of the course of disease progression in menstrual
TSS. (1) Staphylococcus aureus colonize the vaginal epithelium within a network
of extracellular matrix; (2) The bacteria secrete TSST-1; (3) The toxins pass
through leaky regions of the epithelial layer affected by inflammation (3a) or bind
directly to surface epithelial cells and undergo receptor-mediated endocytosis
(3b), after which they enter the blood.
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1.3.5.2.

S. aureus Colonization

The microenvironment of the vaginal epithelium consists of exposed
epithelial cells with surrounding extracellular matrix (ECM) and vaginal secretions
containing proteins, polysaccharides, organic acids, glycerol and urea (Owen &
Katz, 1999). The main mechanism of S. aureus attachment to mucosal surfaces,
and thus the initial step to tissue colonization, is binding to epithelial cell
receptors and components of the ECM. These interactions are mediated by a
family of cell surface adhesins on S. aureus that bind to the extracellular matrix
(ECM), which are collectively known as microbial surface components
recognizing adhesive matrix molecules (MSCRAMMs) (Patti et al., 1994).
Staphylococcus aureus utilizes a collection of MSCRAMMs to bind multiple
components of the ECM, including fibronectin (Espersen &Clemmensen, 1982;
Flock et al., 1987), collagen (Holderbaum et al., 1985; Patti et al., 1992), laminin
(Vercellotti etal., 1985), vitronectin (Chhatwal etal., 1987; Paulsson et al., 1992),
and elastin (Park et al., 1991). Fibronectin, a glycoprotein that is bound to
integrin on epithelial cells and is a common component of ECM, has been
extensively studied as a ligand for S. aureus attachment (Kuusela, 1978; Proctor
et al., 1982; Ryden etal., 1983).Today, two proteins in particular, fibronectinbinding proteins A and B (FnBPA and FnBPB, respectively) have been found to
effectively bind fibronectin, fibrinogen and elastin (Jonsson et al., 1991; Roche et
al., 2004; Wann et al., 2000). These MSCRAMMs, along with various
polysaccharide adhesins, are also responsible for the initial stages of biofilm
formation, which appears to aid vaginal colonization (Costerton, 2005; Gotz,
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2002; Veeh et al., 2003). Thus, S. aureus is capable of attaching itself to multiple
components of the vaginal environment, including epithelial cells and the ECM,
and can at times persist for longer periods through the generation of biofilms.
In a study of 600 women, with the majority at ages 16-35 years
(Linnemann et al., 1982), vaginal colonization, including the canal and labia, was
seen in 9% of the population, and vaginal colonization of TSST-1-producing S.
aureus was present in 1%. Interestingly, greater S. aureus colonization was seen
in black women (14%) compared to Caucasian women (6%), and the
subpopulation with the greatest rate of colonization was postpartum (17%).
A more recent study investigated the nature of S. aureus colonization at
various body sites in premenopausal women, including the nares, vagina and
anus, with colonization rates near identical to that found by Linnemann et al.
(1982) (Parsonnet et al., 2005). Staphylococcus aureus was found to colonize
26% of the participants, with a total of 9% of women being colonized vaginally.
Black women were found to have a higher vaginal colonization rate (14%) than
that of Caucasian women (8%). Of all women enrolled, approximately 1% were
colonized vaginally with a TSST-1-producing strain of S. aureus.
Another study analyzed vaginal-rectal samples from 2,963 pregnant
women, and identified S. aureus colonization in 17.1% of this population (Chen et
al., 2006). They also found that S. aureus colonization was significantly
associated with colonization with Streptococcus agalactiae, or group B
Streptococcus (GBS), reflected by the finding that 6.4% of this population was
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colonized with both organisms. Thus, it appears that S. aureus colonizes 9% of
premenopausal women vaginally in North America, with a higher rate of
colonization seen in black, pregnant and postpartum women.
However, it is not well understood which proportion of the vaginal
microbiota within an individual is made up from S. aureus when it is present,
whether it constitutes a small fraction or acts as the predominant member. This is
important when considering the vaginal state during the initial stages of
menstrual-TSS progression.
1.3.5.3.

TSST-1 Production

Toxic shock syndrome toxin-1 is encoded by tst, a gene located on various
mobile S. aureus pathogenicity islands (SaPIs), namely SaPI1, SaPI2, SaPIbovI,
SaPInl and SaPIml (Novick et al., 2010). The expression of tst, along with
several other virulence factors in S. aureus, is tightly controlled by two families of
global regulators: two-component regulatory systems (TCRS) and the DNAbinding SarA protein family (Cheung et al., 2004).
TCRSs are common stimulus-response systems employed by many
bacteria to detect environmental conditions. A major virulence regulator under the
control of a TCRS is the agr (accessory gene regulator) locus which is
responsible for controlling the expression of tst and other virulence factors. This
system takes part in the quorum sensing (QS) of S. aureus; that is, the detection
of environmental cues and communication with surrounding bacteria. It drives
production of adhesion factors during exponential phase, and exotoxins and
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other virulence factors during late-exponential phase (Dunman et al., 2001).
Thus, when S. aureus first comes into contact with the host, agr genes encode
factors to help with adherence to the tissue. Once bacterial numbers reach a
threshold density, toxins are produced that will help the bacteria evade the host
defenses and spread to other areas. This locus is made up of the P3 and P2
operon, which drive transcription of hid and agrBDCA, respectively. The latter
encodes a QS system and TORS, encoded by agrBD and agrAC, respectively.
This operon is responsible for the production and sensing of auto-inducing
peptides (AlPs), which are detected by the system’s sensory component, AgrC.
This, in turn, leads to phosphorylation of the activator, AgrA, which then binds to
the P2 and P3 promoters, driving cyclic activation of the system. Initiation of
RNAIII transcription (the effector molecule of the system) by the P3 promoter
leads to the production of various exotoxins (including TSST-1) and suppression
of cell-surface adhesins. Thus, as bacterial density increases, a local build-up of
AlPs will lead to concurrent activation of RNAIII. This system not only detects
bacterial density but also monitors environmental stresses, and can therefore
orchestrate the most appropriate production of virulence factors in response to
local stimuli. Other TCRSs shown to regulate the agr locus include SrrAB
(Yarwood et al., 2001) and ArIRS (Fournier et al., 2000), which both counteract
agr activity.
SarA is a dimeric DNA-binding protein that, together with a family of
homologues, plays a role of virulence regulation in S. aureus, including the
regulation of agr. At high levels, this protein binds to the P2 and P3 promoters of
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the agr locus and drives transcription of RNAII and RNAIII, respectively (Chien &
Cheung, 1998). This protein also binds directly to the tst promoter and thus
drives tst expression both directly and indirectly through increased RNAIII
production (Andrey et at., 2010). Rot (Repressor of toxins), a SarA homologue,
has anti-agractivity and down-regulates secretion of toxins, while up-regulating
cell surface proteins (Said-Salim et al., 2003).
Other factors shown to affect the agr system include the alternative sigma
factor B (ctb), which is a transcription initiation factor that plays a role in bacterial
stress response and demonstrates anti-agr activity, reflected by its ability to
down-regulate exoprotein expression in S. aureus (Nicholas et al., 1999). The
TRAP system is a QS system that was believed to regulate agr, made up of
RNAIII-activating protein (RAP) and RNAIII-inhibiting protein (RIP) which were
thought to cause up- and down-regulation of RNAIII, respectively (Balaban &
Novick, 1995; Korem et al., 2003). However, recent findings find no link between
these two systems (Shaw et al., 2007). The regulation of TSST-1 production in S.
aureus is therefore a complex process involving many factors (Figure 1.2).
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Figure 1.2. Schematic diagram showing the regulation of the agr system and
exotoxin production in S. aureus. Figure obtained from Yarwood and Schlievert
(2003).
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A number of environmental factors have been identified that affect the
induction of TSST-1 in S. aureus, including oxygen and carbon dioxide levels,
environmental pH and magnesium ion concentration.
A study by Ross and Onderdonk revealed that TSST-1 production by S.
aureus was triggered by elevated oxygen levels, and that the presence of both
oxygen and carbon dioxide were required for toxin production (Ross &
Onderdonk, 2000). Another study tested TSST-1 production across a range of
oxygen levels in the presence and absence of carbon dioxide (Yarwood &
Schlievert, 2000). In the absence of carbon dioxide, TSST-1 production reached
a maximum of 500 ng/ml_ at 15 mm Hg oxygen and this dropped as oxygen
levels increased. However, in the presence of 53 mm Hg carbon dioxide, TSST-1
production was proportional to oxygen content, reaching 1,900 ng/ml_ at 159 mm
Hg oxygen. Therefore, production of TSST-1 is enhanced by elevated oxygen
and carbon dioxide levels.
There has also been an established link between TSST-1 production and
pH. Cultures of S. aureus cultures have been assessed against a range of pH
values from 4.0-8.0, with the result that TSST-1 production increases to a
maximum at a neutral pH of 6.5-7.0, after which it starts to decrease (Sarafian &
Morse, 1987). This phenomenon of optimal TSST-1 production at a neutral pH
was confirmed by others (Wong & Bergdoll, 1990). In vivo evidence of neutral pH
being optimal for toxin production has also been presented: clinical samples of
lesions from 4 patients with TSS had physiological characteristics matching
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optimal in vitro conditions for TSST-1 production, including a pH range of 6.75
7.45 and elevated oxygen and carbon dioxide levels (Todd eta!., 1987).
Magnesium ions have been shown to have a suppressive effect against
TSST-1 production. The first demonstration of this phenomenon was seen in an
experiment testing the effect of tampon fibers on TSST-1 production (Mills et al.,
1985). Addition of fibers from the Rely® tampon to a culture of S. aureus led to an
increase in TSST-1 production, which was linked to the removal of magnesium
ions from the medium. Addition of the ion led to a suppression in TSST-1
production. The same group confirmed the suppressive nature of magnesium ion
concentration on TSST-1 production in environments of variable oxygen levels
and temperature (Kass et al., 1987). Others found that TSST-1 production was
highest at a magnesium concentration of 0.4 mM, but then decreased as the
metal concentration was further increased (Sarafian & Morse, 1987).
1.3.5.4.

TSST-1 Translocation

A vital step in the pathogenesis of menstrual-TSS is translocation of
TSST-1 across the vaginal epithelium into the bloodstream. It was initially
discovered that TSST-1 binds to epithelial cells and is internalized into the
cytoplasm through receptor-mediated endocytosis, after which it is translocated
through special transport vesicles different from receptosomes (Kushnaryov et
al., 1984). Research has investigated the particular mechanism responsible for
toxin binding to the epithelial cells, as well as contributing factors for
translocation. In particular, a dodecapeptide region in the amino acid sequence
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of TSST-1, F119-D130, has been implicated in transcytosis of this toxin across
the vaginal epithelial cells as well as triggering of inflammatory cytokines from
these cells (Brosnahan et al., 2008). This latter process is believed to contribute
most to TSST-1 translocation as the pro-inflammatory cytokines that are induced
(TNF-a, IL-8 and MIP-3a) increase permeability of the epithelial layer (Peterson
et al., 2005). Staphylococcus aureus also secretes a cytolysin, a-toxin, which has
been shown to induce an inflammatory response at the nonkeratinized stratified
squamous epithelial surface of the vaginal wall and lead to increased
translocation of TSST-1 (Brosnahan et al., 2009). The event of TSST-1
translocation therefore seems to occur in two ways: 1) receptor-mediated
endocytosis into vaginal epithelial cells and subsequent transport through the
cell, and 2) passive transfer of the toxin across leaky regions of the vaginal
epithelium.
1.3.6. Antibody Titres to TSST-1

In the event that S. aureus is successful in colonizing the vagina and
produces TSST-1, which then translocates across the vaginal epithelium and
enters the bloodstream, many women are protected with anti-TSST-1 antibodies
(Parsonnet et al., 2005). This study found that 85% of women had a positive
TSST-1 antibody titre, defined as a titre with a dilution ratio of 1:32 or lower.
Seventy-nine percent of subjects aged 13-15 years (typical age when
menstruation begins) had positive antibody titres. More women had a positive
titre when colonized with TSST-1-producing S. aureus (98%) than when
colonized with TSST-1-negative S. aureus (84%). Interestingly, when the study
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compared carriers of TSST-1 -producing S. aureus, fewer black women had a
positive antibody titre (89%) than Caucasian women (98%). Therefore, evidence
suggests that black women may be more susceptible to menstrual-TSS on the
basis of increased vaginal colonization of S. aureus and decreased positive
TSST-1 antibody titres compared to Caucasian women. The reason for this
different antibody response is unclear.
Thus, most women of premenopausal age seem to be protected from the
effects of systemic TSST-1, including girls at an age when they first use tampons.
Studies have confirmed the absence of circulating antibodies to TSST-1 in
women who develop menstrual-TSS (Stolz et al., 1985). In this study, 86 of 95
patients (90.5%) with menstrual-TSS were essentially lacking anti-TSST-1
antibodies, highlighting the importance of TSST-1 antibody titres for resistance of
menstrual-TSS.
1.3.7. The Tampon Hypothesis

It is widely accepted that menstrual-TSS is linked to tampon use.
Menstrual-TSS was first recognized as a result of the introduction of highabsorbency tampons (Schlech et al., 1982), and 98% of patients with TSS report
the regular use of tampons (Hajjeh et al., 1999). Studies have also found S.
aureus biofilms (Veeh et al., 2003) and TSST-1 (Schlievert et al., 2010) on
tampon fibers following insertion. It is not completely understood, however, why
tampons increase the susceptibility of menstrual-TSS. Two prominent theories
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exist which consider the influence of environmental conditions on TSST-1
production.
The first theory considers the finding by Yarwood and Schlievert (2000)
that TSST-1 production is proportional to oxygen content. Tampon insertion
during menstruation was initially believed to introduce a bolus of oxygen into the
vagina, raising oxygen levels to near-atmospheric levels; following tampon
insertion, vaginal oxygen levels increased from 3 mm Hg to 130-140 mm Hg
(Wagner et al., 1984). A recent study, however, demonstrated that the rise in
oxygen was most likely due to gas level detection in the tampon itself, and that
oxygen levels in the vaginal canal actually decreased upon insertion (Hill et al.,
2005). This research group found that the partial pressure of oxygen decreased
from an initial 15-35 mm Hg to 1 mm Hg after insertion (subjects in this study
included women who were previously pregnant, and so had a higher partial
pressure of oxygen than typically seen). The same study verified oxygen at
atmospheric levels in inserted tampons. Therefore, considering that S. aureus
and TSST-1 have been found on tampon fibers, it is possible that the pathogen
colonizes the tampon and gains access to the high levels of oxygen content
within the device, rather than being introduced to an overall elevated aerobic
environment in the vaginal canal.
Another prominent theory to why tampons contribute to menstrual-TSS is
that tampons absorb magnesium ions in the vaginal canal, effectively decreasing
its concentration and thereby inducing TSST-1 production. In support of this
theory, Mills et al. (1985) found that tampon fibers absorbed magnesium ions and
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increased TSST-1 production as a result. Further studies validated this
suppressive effect of excess magnesium ions in vitro (Kass et al., 1988; Mills et
al., 1986). Although this might contribute in part to increased toxin production
upon tampon insertion, more in vivo work detecting vaginal magnesium ions
should be done before making any definite conclusions.
The effects of different materials used to make tampons, as well as their
absorbency, on S. aureus growth and TSST-1 production have been
investigated. Tampons are made from one of three compositions: cotton, cotton
rayon and rayon. A study of the effects of cotton tampons on TSST-1 production
found that these fibers prevented production of the toxin while cotton-rayon and
rayon induced production, making cotton the safer of the fiber types (Tierno &
Hanna, 1994). However, two subsequent studies disproved this theory, showing
that neither of the three tampon compositions increased production of TSST-1
(Parsonnet et al., 1996; Schlievert, 1995). Another aspect of tampon design of
interest was absorbency, considering that menstrual-TSS first emerged from the
introduction of a highly-absorbent tampon. Tampons sold in North America are
available in five different absorbency strengths, ranging from 6 grams and under
(junior absorbency) to 15-18 grams (ultra absorbency) of menstrual fluid
absorbance. The study by Parsonnet et al. (1996) altered its experimental design
to test for effects of absorbency and showed that a super plus absorbency (12-15
grams) lead to slightly higher levels of TSST-1 in a S. aureus culture compared to
tampons made of the same material but of a lower absorbency rating. The study
by Schlievert (1995), as well as a case control study from the late 1980s
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(Reingold et al., 1989), also suggests that an increase in tampon absorbency
leads to a higher incidence of menstrual-TSS.
Conclusive in vivo work is still missing in this field of research, and there is
still a need to either revise the design of the tampon or develop other approaches
to prevent all cases of menstrual-TSS. As the composition of the tampon seems
to have a minimal effect on TSST-1 production, and usage of low-absorbency
tampons seems effective at keeping the risk of menstrual-TSS relatively low,
investigations might consider oxygen and magnesium ions, and the role of other
vaginal microbes.
1.4. Vaginal Microbiota

1.4.1. Definition

The vaginal microbiota is a community of bacteria that reside in the vagina
and play a role in disease as well as protection from infection by pathogenic
bacteria, viruses and fungi. Most members of the microbiota are thought to derive
from migration of bacteria from the rectum to the vagina via the perineum, but
bathing, sexual contact and clothing are other potential sources. The
predominant bacteria in this population are those from the genus Lactobacillus,
members of the lactic-acid bacteria (LAB) group (Lamont et al., 2011).
Lactobacilli belong to the phylum Firmicutes (low G-C content, Gram-positive
bacteria), class Bacilli and order Lactobacillales. Recent advancements in
molecular, cultivation-independent sequencing methods have shed light on the
species and abundance of the microbiota population (Gloor et al., 2010). The
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species found most often in the healthy vaginal microbiota are Lactobacillus
crispatus, L. jensenii and L iners, with the latter also abundant in BV (ZozayaHinchliffe et al., 2010). Under estrogen influence, glycogen is produced by
vaginal epithelial cells, metabolized by lactobacilli and converted to lactic acid
through the fermentation of glucose. This in turn maintains the vagina at a pH of
approximately 3.8-4.5. The resulting acidic pH serves as a broad protective
mechanism against the growth and colonization of pathogenic bacteria in the
vagina. Other protective mechanisms include displacement of pathogens
(McMillan et al., 2011), immune modulation (Christensen et al., 2002; Sung Kim
et al., 2006), production of anti-microbial agents such as hydrogen peroxide
(Klebanoff et al., 1991), bacteriocins-like substances (McGroarty & Reid, 1988)
and biosurfactants (Reid et al., 1993; Velraeds et al., 1996).
Evidence suggests that the vaginal microbiota varies amongst racial
groups. A study by Zhou et al. (2007) found only 68% of black women had a
Lactobacillus-dominated microbiota, as compared to 91% of Caucasian women,
which could account for the higher incidence of BV seen in black women
(Allsworth & Peipert, 2007). Zhou et al. (2010) found Lactobacillus-dominated
populations in 75% of Japanese women, consisting primarily of L. Iners, L.
crlspatus, L. jensenii, L. gasseri and L. crispatus. Another study found
Lactobacillus-dominated vaginal populations in 80.2% and 89.7% of Asian and
Caucasian women, respectively, but only 61.9% and 59.6% of black and
Hispanic women, respectively (Ravel et al., 2011). Possible reasons for inter
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racial differences in the vaginal microbiota include differences in host genetics as
well as cultural and behavioral nuances.
Menses has been shown to temporarily alter the vaginal microbiota. At
mid-cycle, estrogen levels and glycogen content peak, and lactobacilli numbers
are expected to be at their highest (Farage & Maibach, 2006). In contrast, the
end of the menstrual cycle sees a drop in estrogen, as well as the delivery of
blood which, at a neutral pH, can significantly alter the microbiota. A recent study
utilized quantitative polymerase chain reaction (PCR) to detect changes in
members of the microbiota throughout menses of healthy women (Srinivasan et
al., 2010). There was an increase in non-Lactobacillus spp., including G.
vaginalis, and reduced amounts of L. crispatus and L. jensenii associated with
menses. Eschenbach et al. (2000) reported heavy growth of Lactobacillus spp. in
84% of healthy women during the postovulatory phase, which decreased to 70%
during menses, while the number of subjects with non-Lactobacillus spp.
increased from 40% to 72%. In particular, Prevotella spp. increased from 28% in
subjects at the postovulatory phase to 56% at menses. Subjects with BV saw a
slight decrease in Lactobacillus spp., from 54% during postovulatory phase to
33% at menstruation, while Prevotella spp. and other non-lactobacilli remained
relatively constant throughout the menstrual cycle. Thus, menstruation seems to
promote fluctuations in the vaginal microbiota, including a reduction in lactobacilli
numbers and increased complexity as a result of menses.
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1.4.2. Techniques used to decipher the vaginal microbiota

The advancements in identification techniques for the vaginal microbiota
made especially over the past 10 years have allowed us to better understand the
bacteria that make up this community. Back in 1960, use of phenotypic assays
such as sugar fermentation and other biochemical characteristics resulted in L.
acidophilus being identified as the main constituent of the microbiota (Rogosa &
Sharpe, 1960). This led to the belief that L. acidophilus was important in vaginal
health. However, the sub-division of the L. acidophilus group into six different
species (L. acidophilus, L. amylovorus, L. crispatus, L. gallinarum, L. gasseri and
L. johnsonii) emphasized the inaccuracy of the belief (Fujisawa et a!., 1992).
Utilizing whole-chromosomal DNA probes, L. crispatus and L. jensenii were
found to be the predominant members of the vaginal lactobacilli (Antonio et a!.,
1999). However, this conclusion was based upon isolating and growing the
lactobacilli, and thereby it failed to detect fastidious organisms. Also, the use of
whole-chromosomal DNA probes requires the user to pre-select the organisms
they wish to identify, which makes this method inappropriate for exploratory
analysis of identifying any and all bacteria present.
More recent studies have utilized culture-independent molecular
techniques to better identify constituents of the vaginal microbiota, the first of
which was reported using denaturing gradient gel electrophoresis (DGGE)
following PCR amplification of 16S rRNA segments of vaginal bacteria (Burton &
Reid, 2002). Methods have also included cloning and sequencing 16S rRNA
fragments following PCR to compare to a database for bacterial identification
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(Hyman et al., 2005; Verhelst et al., 2004; Zhou et a!., 2004). In 2007, use of 16S
rRNA gene terminal restriction fragment length polymorphism (RFLP)
fingerprinting was reported to identify bacteria in the healthy and BV vagina, with
a total of 23 species making up those of BV subjects and only 3 from healthy
subjects (Thies et al., 2007). An advantage of DGGE, however, is that it is less
time consuming and more cost-effective than cloning, and allows for effective
comparisons of bacterial diversity across many samples (Burton & Reid, 2002;
Burton et al., 2003; Ferris et al., 2004). A disadvantage of this method is that
organisms of low abundance may not be detected, and the abundance threshold
below which a species is not detected is of yet unknown.
A recent revolutionary advancement in the identification of vaginal
microbiota is the use of metagenomics, a deep-sequencing approach that is able
to reveal virtually all bacteria present in a sample, regardless of abundance. A
study by Sundquist et al. (2007) was the first to analyze vaginal samples using
high-throughput pyrosequencing, and established the general protocol for this
approach. Spear et al. (2008) used pyrosequencing to sequence vaginal
bacterial profiles, by collecting samples from BV-positive and BV-negative
women infected or not infected with HIV, and was able to detect a total of 35
different taxa (range of 8-18 in BV and 1-4 in healthy). A recent study by our
group was the first to use 16S rRNA sequencing by lllumina to examine the
impact of antibiotic therapy on the vaginal microbiota (Hummelen et al., 2010).
Sequencing results from this study found a total of 60 phylogenetic groups within
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the samples, and the method was able to identify to the strain level for some
species.
Thus, the techniques used today to unravel the constituents of the vaginal
microbiota are culture-independent and are able to detect the presence of
bacteria at low abundance. Although it is presumed that techniques such as
DGGE are unable to detect bacteria in low numbers, it is unclear exactly how
abundant these bacteria need to be in a sample. Before the field can take a
confident step towards next-generation sequencing, a comparison should be
made between DGGE and high-throughput sequencing using DNA from the
same sample pool.
1.4.3. Aberrant States

Changes in the vaginal environment, such as varying glycogen levels in
the mucosa, render the vaginal microbiota susceptible to constant fluctuations in
its members. Although this is a normal and inevitable process, the microbiota is
at risk of falling into certain aberrant states characterised by a depletion of
lactobacilli and a subsequent increase in pathogenic bacteria. Two such states
are bacterial vaginosis (BV) and aerobic vaginitis (AV).
1.4.3.1.

Bacterial Vaginosis

Bacterial vaginosis is the most common aberrant vaginal condition,
afflicting an estimated 29% of North American premenopausal women and up to
71% of some populations of sex workers (Ramjee et al., 1998). The incidence of
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this condition differs among ethnic groups: BV is present in 23% of Caucasian
women, 32% of Mexican Americans, and 51.4% of black women (Koumans et al.,
2007). This condition is characterized by a depletion in lactobacilli abundance,
with the exception of L. iners, and an increased bacterial complexity and
abundance of anaerobic bacteria, including Gardnerella vaginalis, Atopobium
vaginae, Prevotella bivia and Leptotrichia amnionii (Fredricks et al., 2005;
Hummelen et al., 2010). In this condition, the vaginal environment becomes
anaerobic and less acidic, with a pH greater than 4.7. Irrespective of symptoms
including vaginal discharge, irritation and a fishy odor, BV has been associated
with increased susceptibility to sexually transmitted infections (STIs), preterm
labour (Holst et al., 1994) and pelvic inflammatory disease (Gomez et al., 2010;
Ness et al., 2005). There have been numerous behavioral characteristics linked
with BV, including having multiple sex partners, receptive oral sex, sexual activity
with a female partner, not using a condom, smoking, using an intrauterine device
and douching (Brotman et al., 2008; Schwebke JR et al., 1999; Smart et al.,
2004).
The gold standard for diagnosis of BV is the Nugent scoring method,
whereby a vaginal swab is smeared onto a glass slide, Gram-stained, viewed
under a microscope and scored based on the proportion of Gram-positive rods
(lactobacilli), Gram-variable rods (Gardnerella spp.) and Gram-negative curved
rods (Mobiluncus spp.) (Nugent et al., 1991). However, current knowledge of the
diverse populations that can make up the BV microbiota indicates that
diagnosing this condition based on the presence of Gardnerella spp. alone

neglects the possible presence of such bacteria as A. vaginae, Prevotella spp.,
Leptotrichia spp. and others (Dols eta/., 2011). Furthermore, BV-associated A.
vaginae are Gram-positive rods, and they could be misidentified as lactobacilli
thereby causing a BV score to be read as normal (Burton et al., 2004). Another
common and more clinically-based diagnosis method is the Amsel criteria, which
is based on the presence of a milk-like discharge, odor, a pH greater than 4.5
and the presence of epithelial cells covered in Gram-negative rods (clue cells)
(Amsel et al., 1983). Other tests have emerged, such as the BVBIue test which
detects the levels of sialidase, a microbial enzyme elevated in BV (Briselden et
al., 1992; Myziuk et al., 2003), and the FemExam that detects elevated pH and
presence of trimethylamine, the compound responsible for the fishy odor linked
with BV (Reid et al., 2004). None of these tests are ideal, and so clinical studies
should preferably include two or more differential tests and should at least
measure pH and the microbiota composition.
Treatment of BV typically includes the use of 500 mg oral metronidazole or
clindamycin twice daily for 7 days and occasionally intra-vaginal metronidazole
gel (CDC et al., 2006). However, none of these approaches prevent recurrence
of BV, which is a common occurrence. One study treated BV with the typical
regime of oral metronidazole and found that 58% of patients experienced
recurrences, with 69% having an abnormal vaginal microbiota after 12 months of
treatment (Bradshaw et al., 2006). A few recent studies have shown that the use
of probiotics, either alone or with antibiotics, can improve the treatment of BV and
reduce recurrence rates (MacPhee et al., 2010). Mastromarino et al. (2009)
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found that giving one tablet containing L. brevis CD2, L. salivarius subsp.
salicinius FV2 and L. plantarum FV9 (>109CFU each) daily for 7 days
significantly improved BV cure rate after 7 and 21 days, compared to giving
placebo alone. Another study tested the effectiveness of oral tinidazole with 2
capsules containing L. rhamnosus GR-1 and L. reuteri RC-14 (109 CFU each)
with the resultant significant increase in cure rate of BV compared to the
antibiotic alone (Martinez et al., 2009). Probiotics have also been shown to
prolong the time until a relapse occurs when they are applied vaginally following
typical metronidazole treatment (Marcone etal., 2008). Therefore, the use of
probiotics for BV treatment and prevention is increasingly becoming a viable
alternative to the use of antibiotics alone, and could potentially improve the
quality of life for these patients.
1.4.3.2.

Aerobic Vaginitis

Aerobic vaginitis is also characterized by depletion in members of the
Lactobacillus genus and an increased pH, but this condition differs from BV in
several ways. Colonization by enteric aerobic commensals such as Escherichia
coli, Streptococcus agalactiae, Enterococcus faecalis and Staphylococcus
aureus is one feature (Donders, 2002). The condition is also characterized by a
local immunological response, reflected in increased levels of pro-inflammatory
cytokines IL-1, IL-6 and IL-8, and the resulting presence of dead epithelial cells
when viewed under microscopy. Aerobic vaginitis has been strongly associated
with pregnancy complications, including preterm birth (PTB), preterm rupture of
membranes, chorioamnionitis, funisitis, miscarriage and low birth weight (Carey &
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Klebanoff, 2005; Donders et al., 2009; Hay et al., 1994; Rezeberga et al., 2008).
Clinical signs of this condition differ slightly from BV, with patients usually
reporting a yellow discharge and a rotten rather than a fishy odor. Patients also
experience a burning sensation (rather than itching as experienced in BV) noted
in vulvovaginal candidiasis (W C), as well as dyspareunia (painful intercourse).
The vagina often appears red and inflamed, and may have ulcers on the wall.
Severe AV can lead to a pH greater than 6.0, compared with a pH of 4.7-6.0
associated with BV.
Diagnostic options for AV are limited, in part because it has only recently
been recognised as a condition separate from BV, W C and trichomoniasis
(Donders, 1999). An aberrant vaginal condition is diagnosed as AV with the
following microscopic findings: decreased lactobacilli, increased leukocytes,
leukocytes with toxic appearance (full of lysosymic granule), presence of cocci or
chains, and parabasal-type epithelial cells (resulting from epithelial inflammation).
The most effective treatment for AV has yet to be established, but
metronidazole is ineffective (Donders et al., 2002), as is expected since this
antibiotic is designed for anaerobic bacteria and protozoa. Misdiagnosis of AV as
BV is thus a problem, since treatment with metronidazole will be ineffective.
Investigators tested the use of two intravaginal antibiotics, kanamycin and
meclocycline, in treating AV in non-pregnant women, and found kanamycin to be
most effective at alleviating clinical symptoms and normalising the vaginal pH
(Tempera et al., 2004). However, monitoring of the microbiota and symptoms of
these subjects stopped only 9 days following the last treatment, and so the AV
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recurrence rate was not assessed. No study with probiotics has yet been
performed to restore the vaginal microbiota in AV subjects. Treatment using anti
inflammatory medication should provide some relief, and combined with
antibiotics and restoring the vaginal microbiota with lactobacilli, should become a
standard approach for management in the future.
1.5. Rationale for studying S. aureus TSST-1 production in aberrant
states

Given that aerobic bacteria, including S. aureus, can colonize the vagina
in otherwise healthy women and those with either AV or BV, manufacturers of
tampons face an important dilemma. Their products are widely used and
extremely effective for managing menses, but they can never be fool-proof at
preventing menstrual-TSS from occurring. It is difficult to control oxygen levels or
magnesium, and unclear as to how big a difference it would make in preventing
menstrual-TSS. However, it could be feasible to attempt to control the vaginal
microbiota in a way that reduced the spread and toxin production of S. aureus.
Clearly, lactobacilli can inhibit the growth of urogenital pathogens E. coli, E.
faecalis and S. aureus (Coconnier efa/., 1997; Gopal etal., 2001; Reid et al.,
1988; Reid, 2001; Velraeds et al., 1996; Voravuthikunchai et al., 2006). More
specifically, a vaginal probiotic L. reuteri RC-14 has been shown to produce
cyclic dipeptides that suppress TSST-1 production in S. aureus (Li et al., 2011).
This anti-virulence activity holds great potential to prevent TSS from occurring.
Meanwhile, studies are needed to assess whether disruption of the vaginal
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microbiota, in particular onset of BV and AV, provides S. aureus with a window of
opportunity to secrete TSST-1 and put the host at risk of menstrual-TSS.
1.6. Hypothesis and Objectives

We hypothesize that aberrant vaginal microbiomes, most notably BV
and AV, contribute to increased TSST-1 production in S. aureus and an
increased susceptibility to menstrual-TSS.
Based upon the healthy vaginal microbiota, consisting of several Lactobacillus
species, their production of antibacterial compounds, and in some cases cyclic
dipeptides (Li et al., 2011), we believe that depletion of these organisms will lead
to increased virulence of S. aureus in the context of menstrual-TSS.
Objective 1: Compare techniques to effectively determine the composition
and abundance of the vaginal microbiota of premenopausal women.
The goal here is to identify the prevalence and abundance of S. aureus in
clinical samples from healthy women and those with an aberrant vaginal state. In
doing so, we wanted to compare DGGE with high-throughput sequencing and
determine which technique gives the most reliable and accurate identification
power.
Objective 2: Determine the nature of fsf expression in S. aureus in
response to aberrant vaginal environments.
We investigated the nature of toxin production by S. aureus when this
organism is exposed to a lactobacilli-abundant vaginal sample versus conditions
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depicting a depletion of lactobacilli. This will help to identify whether some
aberrant conditions make a woman potentially more susceptible to developing
menstrual-TSS.
Objective 3: Determine the nature of TSST-1 production in response to
representative members of the healthy, BV and AV microbiota.
The final step in this study was to perform in vitro testing of vaginal
bacterial strains against S. aureus to identify groups of bacteria with inducing,
neutral and inhibitory effects on TSST-1 production. If certain organisms
influence TSST-1 production, efforts could be made to detect their co-existence
with S. aureus in women at risk of menstrual-TSS, and to target interventions that
neutralize this threat.

CHAPTER 2

MATERIALS AND METHODS
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2.1. Denaturing Gradient Gel Electrophoresis

2.1.1. Clinical Samples

Vaginal samples were collected from HIV+/- and BV+/- women recruited in
Tanzania, Africa, as part of another study (Hummelen et al., 2010). Sequencing
by lllumina was used to analyse the samples, separate from my involvement. For
my project, a total of 22 of these vaginal samples were randomly selected for
subsequent DGGE analysis, so that results could be compared to sequencing by
lllumina. Of the 22 samples, 8 were healthy, 9 had BV, and 5 had an
intermediate Nugent score.
2.1.2. DNA Extraction and Amplification

Samples were obtained by brushing the vaginal wall with a CultureSwab
polyester-tipped swab (BD Biosciences) with the aid of a non-lubricated
speculum. The swab was placed in a cryovial and stored at -20°C. When DNA
extraction was performed, swabs were thawed and agitated in 1 ml_ PBS (pH
7.5). The solution was centrifuged at 10,000 rpm for 20 min and the supernatant
discarded. Next, 200 pL InstaGene Matrix (BioRad #732-6030) was added to the
bacterial pellet and incubated for 30 min at 56°C. The solution was vortexed for
10 sec and incubated for 8 min at 100°C, then re-vortexed for 10 sec followed by
centrifugation at 10,000 rpm for 30 sec. The supernatant was transferred to a
clean microcentrifuge tube and used as DNA template for subsequent
polymerase chain reaction (PCR). Prior to use, the solution was centrifuged at
10,000 rpm for 3 min to spin down the InstaGene Matrix component of the

solution. PCR amplification of the DNA was carried out in 50 pi reactions
consisting of 1 pL DNA template and 49 pL master mix (Table 2.1).
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Table 2.1. PCR Master Mix for DGGE.

P C R C om p on en t

V o lu m e ad d ed (pL )

F in al C oncentration

10X P CR Buffer (Invitrogen)
M gCl2(50m M )
dNTPs (1.25 mM)
H D A -f (20 pM)
H D A -r (20 pM)
Platinum Taq Polymerase
(5U/pL) (Invitrogen)
dH20

5.0
1.7
8.4
1.6
1.6
0.5

IX
1.7 mM
210 pM
640 nM
640 nM
0.05 U/pL

F in al V olum e:

30.2
49
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A positive and negative control was included in each reaction set
consisting of 1 pL L. iners DNA or 1 pL dH20, respectively, and 49 pL master mix.
Eubacterial primers (HDA) were used to amplify the third variable region (V3) of
the 16S rRNA gene. These primers were HDA-f-GC (5-CGC-CCG-GGG-CGCGCC-CCG-GGC-GGG-GCG-GGG-GCA-CGG-GGG-ACT-CCT-ACG-GGA-GGCAGC-AGT-3’) and HDA-r (5’-GTA-TTA-CCG-CGG-CTG-CTG-GCA-3’). The
forward primer contained a GC clamp (in bold) which is used in DGGE to help
retain double strands while the DNA denatures on the gel. The PCR reactions
were carried out in a Mastercycler (Eppendorf) under the following annealing
temperature touchdown program: 94°C for 2 min, 25 cycles of 94°C for 45 sec,
61°C-51°C over 10 cycles for 45 sec (each cycle dropping by 1°C then remaining
at 51 °C for last 15 cycles), 72°C for 45 sec, and a final elongation step of 72°C
for 2 min. PCR products (5 pL) were mixed with 1 pL 6X Loading Dye and loaded
onto a 1.5% agarose gel made of 1X TBE with 5 pL ethidium bromide. The gel
underwent electrophoresis and was viewed under UV light in an Alphalmager
(Alpha Innotech Corporation) to verify the presence of PCR product in each
sample.
2.1.3. Denaturing Gradient Gel Electrophoresis

A denaturing gradient of 30-50% was used, with denaturant solutions
prepared based on reference 0% and 100% denaturing solutions shown in Table
2.2.
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Table 2.2. Composition of dénaturant solutions used for DGGE.

D én atu ran t Strength

100%

C om p on en t

0%

40% acrylamide/bis-acrylamide
(37.5:1)
50X T A E
Urea
Formamide
m q -h 2o

5 mL

5 mL

0.5 mL

0.5 m L
10-5 R
10 m L
Up to 25 m L

or

0 mL
Up to 25 m L
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The denaturing solutions were prepared in 50 mL Conical tubes (BD
Biosciences) and mixed by gently rocking back and forth to avoid oxygenation.
Polymerizing agents were added, including 50 pL TEMED (N,N, /Vn,/Vntetramethylethylenediamine) (Sigma) and 90 pL of 10% ammonium persulphate
(Bio-Rad). Next, 100 pL of D-Code dye was added to the 50% denaturant
solution to visualize the concentration gradient, and 16 mL of each solution was
taken up in 50 mL syringes and poured into a glass sandwich (D-Code Universal
Detection System, Bio-Rad). A comb was added to the top of the gel which was
then allowed to polymerize for 2 hr at room temperature. The DGGE tank was
filled with Milli-Q H20 (Millipore) and 140 mL 50X TAE, and was heated to 59°C.
After the gel was assembled into the unit, 5 pL sample was mixed with 5 pL 2X
loading dye (0.25 mL bromophenol blue [2%, Sigma], 0.25 mL xylene cyanol
[2%, Sigma], 7 mL glycerol, 2.5 mL dH20) and loaded into the wells .The gel was
run for approximately 4 hours at 130V or until the lower dye front reached the
bottom of the gel. The gel was then removed from the unit and allowed to cool to
room temperature. The gel was placed on a plastic sheet and stained for 20 min
in 600 mL of 1X TAE with 40 pg/L ethidium bromide and viewed under UV light.
DNA bands were excised using a scalpel and placed in separate 1.5 mL
Eppendorf tubes. 20 pL of Milli-Q H20 was used to wash each excised band,
after which another 20 pL was added to the tubes, which were then left at 4°C
overnight to allow for DNA to disperse into the surrounding solution.
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2.1.4. DNA Re-amplification and Purification

Re-amplification of the excised DNA was performed using the same PCR
protocol as described above, but with using an HDA-f primer without the GC
clamp. One microlitre of solution from the DNA band/Milli-Q H20 mixture was
used as template and added to 49 pL master mix (Table 2.1). DNA products
were viewed under UV light as described previously. Purification of the re
amplified DNA was performed using the QIAquick PCR Purification kit (Qiagen).
One hundred microlitres of PB1 buffer was added to 20 pL PCR product and
mixed, then added to a QIAquick column placed in a 2 mL collection tube and
centrifuged at 6,000 rpm for 60 sec to bind the DNA to the membrane. Bound
DNA was washed twice using 750 pL PE buffer and centrifuged at 6,000 rpm
(first wash) and 13,000 rpm (second wash) for 60 sec each. DNA was eluted by
the addition of 50 pL Milli-Q H20 to the centre of the membrane followed by
centrifugation at 13,000 rpm for 60 sec. The eluted DNA was then stored at 20°C until further use.
2.1.5. Sequencing

A mixture was prepared consisting of 10 pL purified PCR product, 0.5 pL
of 20 pM forward primer (HDA-f) and 4.5 pL Milli-Q H20. Sequences of the PCR
products were determined by dideoxy chain termination (Sequencing Facility,
John P. Robarts Research Institute, London, Ontario). Analysis of the V3 region
of 16S rRNA was conducted using the GenBank nucleotide database and BLAST
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algorithm (Altschul etal., 1997). Electropherograms were analyzed using the
FinchTV chromatogram trace viewer (Geospiza).
2.2. Clinical Study of Vaginal Microbiota of Premenopausal Women

2.2.1. Ethics Statement

Details of the clinical study were reviewed and approved by the Health
Sciences Research Ethics Board at the University of Western Ontario (Appendix
1). Participants were provided with a package detailing all relevant information of
the study, including an in-depth explanation of the clinical procedure, and signed
a consent form prior to sample collection.
2.2.2. Study Population and Recruitment

Recruitment of pre-menopausal women between the ages of 18-40 years
with BV as well as healthy controls took place in London, Ontario and was based
on a selective criteria designed to ensure that the vaginal samples reflected a
representative microbiota of the general female pre-menopausal population.
Recruitment posters (Appendix 2) were placed in the following locations in
London, Ontario: The University of Western Ontario, St. Joseph’s Health Care
Centre, Lawson Health Research Institute, Victoria Family Medical Centre,
Victoria Hospital and University Hospital. The poster emphasized a target
audience of premenopausal women with a suspected history of BV.
Communication between the study coordinator and those interested in the study
was through phone and email correspondence. Participants were excluded if
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they had reached menopause, had a urogenital infection other than BV in the
past 6 months, were pregnant, had a history of gonorrhoea, chlamydia, estrogendependent neoplasia, abnormal renal function or pyelonephritis, were taking
prednisone, immune-suppressives or antimicrobial medication, or had
undiagnosed abnormal vaginal bleeding. Participants were asked to refrain from
oral or vaginal intercourse and consuming probiotic supplements or foods for 48
hours prior to the clinical visit. No participants were menstruating at time of the
clinical visit.
2.2.3. Sample Collection

Weekly clinics were held at the Victoria Family Medical Centre (London,
Ontario) over a 6-month period. Participants were first reimbursed with $50 for
attending, and they were given a letter of information and consent package
(Appendix 3) and baseline questionnaire (Appendix 4) which listed the exclusion
criteria. Two nurses collected vaginal samples, and the study coordinator was on
site to first go over the study details and procedure with each participant. A total
of 7 samples were collected from each participant: one pHem-alert applicator
(Gynex) was used to detect the vaginal pH; three CultureSwab polyester-tipped
swabs (BD Biosciences) were used for bacterial isolation (for diagnosis of BV by
Nugent score, for bacterial DNA and RNA collection); two ESwabs (Copan) were
processed for culturing the organisms; and one cytobrush (Cooper Surgical) was
processed for vaginal epithelial cell RNA (Figure 2.1). Swabs were inserted
approximately 5 cm into the vaginal canal, pressed against the wall and rotated 4
times.
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Score

Bacterial Bacterial
DNA
RNA
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RNA
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Figure 2.1. Flowchart of vaginal samples collected during the clinical study held in
London, ON.
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The microbial status was assessed through the Nugent scoring method
(Nugent et al., 1991). A CultureSwab polyester-tipped swab (BD Biosciences)
was pressed against the vaginal wall and smeared onto a glass microscope slide,
heat-fixed and Gram-stained. Slides were viewed under an Axio Scope light
microscope (Zeiss). Each slide was given a score based on the number of 1)
Gram-positive rods, 2) Gram-variable short rods and 3) Gram-negative cocci and
curved rods (indicative of lactobacilli, Gardnerella vaginalis and Mobiluncus spp.
respectively) (Table 2.3). Four fields of view were chosen at random at a
magnification of 1,000 X, and bacterial numbers from each were recorded. The
average number of bacteria in each of the three categories was recorded, and
their corresponding scores were added to obtain a final score. A score of 0-3 was
deemed healthy with predominance of presumptive lactobacilli, 4-6 was
intermediate with fewer presumptive lactobacilli and more Gram-variable short
rods and Gram-negative cocci and curves rods, and 7-10 was BV where the
samples were dominated with non-lactobacilli organisms, usually in biofilms. A
participant was diagnosed as having BV if the Nugent score was 7-10 and if they
had a vaginal pH>4.5.
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Table 2.3. Nugent score criteria for BV diagnosis.

L actoba cillu s spp.
(L arg e G ram 
p ositive rods)

G ardnereU a spp.
(Sm all G ram 
variab le rods)

C ells p er high
p ow er field (xlOOO)

M obilu n cu s spp.
(C urved G ram 
variable rods or
cocci)

SC O R E

SC O R E

SC O R E

0
<1
1-4
5-30
>30

4
3
2
1
0

0
1
2
3
4

0
1
1
2
2
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2.3. Bacterial DNA Preparation for lllumina Sequencing

Bacteria were collected on a CultureSwab polyester-tipped swab (BD
Biosciences) which was immediately placed in 700 pL RNAprotecf (Qiagen). The
tube was vortexed for 5 sec, swab discarded and the solution stored at -20°C.
For DNA isolation, the solution was centrifuged at 10,000 rpm for 20 min and
supernatant discarded. Next, 200 pL InstaGene Matrix (BioRad #732-6030) was
added to the bacterial pellet and incubated for 30 min at 56°C. The solution was
vortexed for 10 sec and incubated for 8 min at 100°C, then re-vortexed for 10 sec
followed by centrifugation at 10,000 rpm for 30 sec. The supernatant was
transferred to a clean microcentrifuge tube and stored at -20°C, before use as
DNA template for subsequent PCR reactions.
PCR was carried out in 50 pL reactions consisting of the same
components and final concentrations as was used with DGGE (Table 2.1) but
with 40 pL master mix and 10 pL template (or 10 pL Milli-Q H20 [Millipore] for
negative control). Amplification was done using eubacterial primers flanking the
V6 region of the 16S rRNA gene: V6-F (5’-CAACGCGARGAACCTTACC -3’) and
V6-R (5’-ACAACACGAGCTGACGAC -3’). Amplification was performed in a
Mastercycler (Eppendorf) using the same annealing temperature touchdown
program as described for amplifying DGGE DNA. Products were viewed via
electrophoresis in a 1.5% agarose gel using 1X TBE, stained with ethidium
bromide and viewed under UV light in an Alphalmager (Alpha Innotech
Corporation). The ImageJ program was then used to quantify the brightness of
each DNA band so that equal amounts of each sample were added to the
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subsequent lllumina reaction. DNA samples were then sent for lllumina
sequencing at The Next-Generation Sequencing Facility in The Centre for
Applied Genomics at the Hospital for Sick Children in Toronto, Canada.
2.4. Luminescence Assay

Vaginal samples were collected from participants using the ESwab
(Conan) swab and transport system containing 1 mL liquid Amies medium
(Figure 2.2). Two ESwabs were each submerged into their respective media for
approximately 2 hours at room temperature followed by a 10 sec vortex at high
speed. The swabs were removed and discarded. One of the solutions was
aliquoted 2 x 350 pL, and 500 pL of cryoprotectant (3% citric acid, 40% glycerol,
pH 7.0) was added to each, and stored at -80°C. These samples would be
available for future culturing of organisms if needed. The other ESwab solution
was aliquoted 2 x 350 pL, with one stored at -80°C and the other centrifuged at
10,000 rpm for 5 min. The supernatant was transferred to a fresh tube and stored
at -80°C, which was later used for the luminescence assay.
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V
V
350 (.iL bacterial solution +
500 pL cryoprotectant

-80°C

V
Centrifuge
10,000 rpm
for 5

V

Pellet

Figure 2.2. Flowchart depicting vaginal swab collection using the ESwab transport
medium, including the origin of sample supernatants for the luminescence assay.
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A culture of a reporter strain of S. aureus MN8, containing the cloning
vector pAmilux with an incorporated promoter for tst, was grown in brain heart
infusion (BHI) media with 10 pg/pL chloramphenicol overnight at 37°C with a
shaking speed of 250 rpm (Mesak et al., 2009; Li et ai, 2011). The culture was
diluted to an OD6oo of 0.02 with a) supernatant from the clinical sample, b) Amies
transport medium or c) BHI, of which the latter two acted as controls. Next, 200
pL of the subculture was grown for 16 hr in a Fluoroskan Ascent FL luminometer
(Thermo) where luminescence production was detected from the activated tst
promoter every 30 min. Another 200 pL of the subculture was also grown in a
Bioscreen C Reader (MTX Lab Systems) at 37°C with continuous shaking for 24
hr to monitor growth of the bacteria.
2.5. Supernatant Challenge Assay

2.5.1. Bacterial Cultures and Conditions

All bacterial strains used in the supernatant challenge assay, along with
respective growth conditions, are listed in Table 2.4. The bacterial strains were
divided into 3 groups for analysis: healthy, AV-associated and BV-associated
bacteria (Table 2.5). The S. aureus MN8 strain was selected as a prototype of
menstrual-TSS strains, as it has been isolated from a pre-menopausal woman
suffering from the condition (Schlievert & Blomster, 1983). All aerobic bacteria
were cultured in shaking conditions for 16 hr at 37°C and then sub-cultured to an
OD6oo of 0.02 using their growth media. The sub-cultures were grown for 12 hr.
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The lactobacilli were grown in anaerobic conditions using the GasPak EZ system
(Becton-Dickenson) for 24 hr at 37°C and sub-cultured for an additional 24 hr,

Table 2.4. Bacterial strains used for supernatant challenge assay.

Bacteria

Source

Staphylococcus
aureus MN8
Escherichia coli J96
Streptococcus
agalactiae ATCC
13813
Enterococcus faecalis
ATCC 33186
Enterococcus faecium
ATCC 19434
Atopobium vaginae

Clinical Isolate

Growth
Media/Conditions
BHI/aerobic

Clinical Isolate
ATCC

BHI/aerobic
BHI/aerobic

ATCC

BHI/aerobic

ATCC

BHI/aerobic

ATCC

Vaginally-Defined
Medium + 0.5%
Proteose Peptone
(VDMP)/anaerobic
VDMP/anaerobic
de Man, Rogosa and
Sharpe
(MRS)/anaerobic
MRS/anaerobic

DSM

MRS/anaerobic

ATCC

MRS/anaerobic

Clinical Isolate

MRS/anaerobic

Clinical Isolate

MRS/anaerobic

N/A*
Prevotella bivia
Lactobacillus
crispatus ATCC
33820
Lactobacillus jensenii
ATCC 25258
Lactobacillus
johnsonii DSM20553
Lactobacillus gasseri
ATCC 33323
Lactobacillus reuteri
RC-14
Lactobacillus
rhamnosus GR-1
Not available/unknown

N/A*
ATCC

Table 2.5. Grouping of bacteria for supernatant challenge assay, based on
associated vaginal condition.

H ealth y (lactobacilli)
L actobacillus jen sen ii
L. g a sseri
L. jo h n so n ii
L. reu teri R C -1 4
L. rham nosus G R -1

G roup
A V -associated
Streptococcus agalactiae
E scherichia coli
E nterococcus fa eca lis
E. faeciu m

B V -a s s o c ia te d

A topobium vaginae
P revotella bivia
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starting at an OD6oo of 0.02. The strict anaerobes, Atopobium vaginae and
Prevotella bivia were cultured and sub-cultured in a Forma anaerobic chamber
(Model 1025, Thermo) for 48 hr at 37°C to allow for adequate growth. Sub
cultures underwent centrifugation at 3500 x gfor 10 min at4°C and the
supernatants were transferred to a fresh tube. The pH of the supernatants were
determined and adjusted to that of the S. aureus MN8 supernatant (pH 5.95),
sterilized via filtration using 0.2 pm filters, transferred to a clean tube and frozen
at -20°C for no longer than 1 week. Next, S. aureus MN8 cultures were grown for
16 hr and sub-cultured starting at an initial OD60o of 0.02 in half BHI and half
supernatant of the challenger bacteria. The sub-cultures were grown for 16 hr at
37°C in shaking conditions and were then centrifuged at 3500xgfor 10 min at
4°C. Sub-cultures were also grown in a Multiskan Ascent Plate Reader (Thermo
Scientific) to detect OD6oo values to ensure similar S. aureus growth across the
various conditions. The supernatants were subsequently used for Western Blot
and real-time PCR.
2.5.2. SDS-PAGE and Western Blot

Total protein from S. aureus supernatant was isolated via trichloroacetic
acid (TCA) precipitation. First, 300 pL of ice-cold 20% TCA was added to 1ml_
supernatant, which was then vortexed at high speed for 5 sec and left on ice for
30 min. The solution was centrifuged at 14,000 rpm for 15 min at 4°C, and the
supernatant discarded. The pellet was washed twice with 300 pL ice-cold
acetone (14,000 rpm for 5 min at 4°C), and was then air-dried and resuspended
in 37.5 pL 200 mM urea and 12.5 pL 4X Laemmli buffer (40% glycerol, 240 mM
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Tris/HCI [pH 6.8], 8% SDS, 0.04% bromophenol blue and 5% betamercaptoethanol). The protein solutions were stored at -20°C until use for gel
analysis.
Acrylamide gels were made for SDS-PAGE (sodium dodecyl sulphate
polyacrylamide gel electrophoresis) and Western blot, each at a lower 12%
resolving gel (pH of 8.8) and an upper 5% stacking gel (pH of 6.8) (Table 2.6).
Protein solutions were thawed and heated at 100°C for 5 min, and then placed
on ice for another 5 min. Next, 20 pL of the protein samples were loaded into the
gels and run at 50V until the bands stacked at the interface of the stacking and
resolving gel, and then at 120V through the resolving gel. The running buffer
consisted of 196 mM glycine, 0.1% SDS and 25 mM Tris-HCI at pH 8.3. When
the lower dye front reached the bottom of the gel, the run was stopped and gels
were removed from the apparatus. One gel was stained in Coomassie Blue stain
solution (50% methanol, 0.05% w/v Coomassie Brilliant Blue R-250 and 10%
acetic acid) for at least 2 hr and then placed in destain solution (5% methanol
and 7% acetic acid) for 2 hr. The gel was then viewed under light on a
transparent surface in an Alphalmager (Alpha Innotech Corporation). The other
gel was soaked in transfer buffer (25 mM Tris [pH 8.3], 192 mM glycine and 20%
methanol) along with sponges, filter paper and the Hybond-ECL nitrocellulose
membrane (Amersham) for protein transfer. The gel and membrane were then
pressed together in between the filter pads and placed in a tank filled with
transfer buffer. A current of 200 mA was run through the assembled unit for 3 hr,
after which the membrane was removed and placed in Ponceau S stain solution
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Table 2.6. Composition of polyacrylamide gels for SDS-PAGE and Western Blot.

C om p on en t
m q - h 2o
40% acrylamide/bis-aciylamide
(37.5:1)
1.5 M Tris (pH 8.8)
10% SD S
(sodium dodecyl sulphate)
10% APS
(ammonium persulfate)
TEM ED
(Tetramethylethylenediamine)

S tack in g G el (5% )

R esolvin g G el (12% )

5.99 m L
1.0 m L

4.3 m L
3.0 m L

750 p L
80 p L

2.5 m L
100 p L

80 p L

100 p L

8 pL

4 pL
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(5% acetic acid and 0.1% w/v Ponceau S) for 5 min and destained in 1X PBS for
15 min to visualize the proper transfer of proteins from the gel to the membrane.
Next, the membrane was placed in blocking solution (5% skim milk and 10%
horse serum in 1X PBS) overnight at 4°C and added to a solution of rabbit IgG
anti-TSST primary antibody (1:1,500) (generously donated by Dr. Schlievert) in
2.5% skim milk and 5% horse serum for 1 hr at room temperature. Following this,
the membrane was washed 3 times with 1X PBS and 0.1% Tween-20 for 5 min
and placed in a solution of goat anti-rabbit IgG-HRP secondary antibody
(1:2,500) (Invitrogen) in 2.5% skim milk and 5% horse serum for 1 hr at room
temperature. The membrane was again washed 3 times with 1X PBS and 0.1%
Tween-20 and exposed to a colorimetric substrate solution (0.0005% [w/v]
diaminobenzidine [DAB], 1ml_ of 1M Tris [pH 7.9], 12 pL H20 2 [30%], 20 mL MilliQ H20) for 3 min to visualize the TSST-1 protein bands.
2.5.3. Real-Time PCR

2.5.3.1.

S. aureus RNA Extraction

A culture of S. aureus MN8 challenged with supernatants from the other
bacteria (as described previously) was grown from an initial OD6oo of 0.02 for 16
hr. Ten millilitres of RNAprotect (Qiagen) was added to 5 mL culture, and the
solution was vortexed and incubated for 10 min at room temperature, then
centrifuged at 6000 x g for 20 min at 4°C (all centrifugation steps in the RNA
isolation procedure occurred at 4°C). The supernatant was then discarded and
the pellet stored at -80°C. To isolate bacterial RNA, the pellet was suspended in
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5 mL lysis solution (10 mM Tris-HCI, 1 mM EDTA [pH 8.0] and 50 pg/mL
lysostaphin) and vortexed. The solution was incubated for 10 min at 37°C then
centrifuged at 6000 x g for 20 min. The supernatant was discarded, and the pellet
was suspended in 5 mL TRIzol (Invitrogen) and vortexed for 2 min. The sample
was incubated at room temperature for 10 min, followed by the addition of 1 mL
chloroform. The solution was vortexed and incubated at room temperature for 10
min, followed by centrifugation at 12,000 x gfor 20 min. Two millilitres of the
upper aqueous phase containing RNA was transferred to RNase-free
microcentrifuge tubes separated into four 500 pL aliquots. Next, 55 pL of 3M
sodium acetate and 550 pL isopropanol was added to each aliquot, the solution
vortexed and incubated at room temperature for 10 min. The sample was
centrifuged at 12,000 x gfor 20 min, supernatant discarded and pellet washed
with 500 pL of 75% ethanol. The pellet was then dried and resuspended in 20 pL
RNase-free H20 and stored at -80°C.
Contaminants were removed from the RNA samples using the RNeasy
Mini Kit (Qiagen). The volume of each RNA sample was adjusted to 100 pL with
RNase-free H20, and then 350 pL RLT buffer was added and mixed. Next, 250
pL 100% ethanol was added to the RNA and mixed with pipetting. Each sample
was transferred to an RNeasy Mini spin column which was placed in a 2 mL
collection tube. The sample was centrifuged at 12,000 rpm for 15 sec and flow
through discarded. Five hundred microlitres of RPE buffer was then added to the
spin column and centrifuged at 12,000 rpm for 2 min. The column was placed in
a new 1.5 mL Eppendorf tube, 30 pL RNase-free H20 added to the column and
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centrifuged at 12,000 rpm for 1 min to elute the RNA. Next, DNase digestion was
performed to remove any DNA contaminants using the TURBO DNA-free Kit
(Ambion). Three microlitres of 10X TURBO DNase buffer along with 1 pL of
TURBO DNase was added to the RNA solutions and mixed. The solutions were
then incubated at 37°C for 30 min, after which 3 pL DNase Inactivation Reagent
was added. These solutions were left at room temperature for 5 min with
occasional mixing before being centrifuged at 12,000 rpm for 1.5 min. The RNA
was transferred to a fresh 1.5 ml_ RNase-free tube.
RNA products were viewed via electrophoresis in a 1% agarose gel using
1X TBE, stained with ethidium bromide and viewed under UV light in an
Alphalmager (Alpha Innotech Corporation). The RNA concentration and quality in
the samples were then determined through a biophotometer (Eppendorf) (RNA
quality cut-off: 260/280 > 1.8; 260/230 > 1.6). Five hundred nanograms of RNA
from each sample was used as a template for reverse transcription PCR.
Conversion to cDNA was done using the Multiscribe Reverse Transcriptase mix
(Invitrogen) with components listed in Table 2.7. The master mix was vortexed
prior to the final addition of the enzyme components of the mix (RNase Inhibitor
and MultiScribe Reverse Transcriptase). The reactions were carried out in a
Mastercycler (Eppendorf) with the following program: initial step of 25°C for 10
min, followed by 37°C for 120 min, and a final step of 85°C for 5 min. The
supernatant challenge experiment was performed once, including three technical
replicates starting from the reverse transcription stage.
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Table 2.7. Master Mix components for MultiScribe Reverse-Transcription.

C om p on en t

V olu m e (pL )

10X TaqMan R T buffer
M gCl2(25 mM)
dNTPs (2.5 mM)
Random Hexamers (50 pM)
RNase Inhibitor (20 U/L)
MultiScribe Reverse Transcriptase
RNase-free H 20

1.0
2.2
2.0
0.5
0.2
0.25
3.85*
10.0

F in al V olum e:

*Subtract by the volume o f RN A used

71
2.5.3.2.

Quantification of tst Expression

The cDNA samples were used as templates for real-time PCR reactions.
Primers included tst-f (5’- CTGATGCTGCCATCTGTGTT -3’) and tst-r (5’GTAAGCCCTTTGTTGCTTGC -3’) for expression of the tst gene, and rpoB-f (5’TCCTGTTGAACGCGCATGTAA -3’) and rpoB-r (5GCTGGTATGGCTCGTGATGGTA-3’) for expression of the rpoB housekeeping
gene. The iQ SYBR Green Supermix (Bio-Rad) was used to carry out 20 pL
reactions, which were composed of the following: 10 pL 2X iQ SYBR Green
Supermix, 1 pL of each primer at 10 pM, 7 pL RNase-free H20 and 1 pL cDNA
template. Reactions were run in a Rotor -Gene 6000 thermocycler (Corbett)
under the following program: an initial melting ramp from 72°C to 95°C, followed
by 40 cycles of 95°C for 10 sec, 60°C for 15 sec and 72°C for 20 sec, ending with
a hold at 95°C for 10 min. Data was analyzed using the Rotor-Gene 6000 Series
Software 1.7 (Corbett). Expression of tst by S. aureus in each condition was
compared to tst expression when S. aureus was grown in media alone. For the
purpose of comparison, the control expression was set at 100%.
A series of standards were created to quantify gene expression during
data analysis. A sub-culture of S. aureus MN8 was grown for 12 hr, and total
DNA isolated using InstaGene Matrix (BioRad #732-6030). PCR was carried out
in 50 pL reactions consisting of the following components: 10X PCR buffer, 1.7
mM MgCI2, 210 mM dNTPs mix, 640 nM of each primer (tst and rpoB primer
pairs used for real-time PCR), 5U Platinum Taq DNA Polymerase (Invitrogen) 5
pL template and Milli-Q H20 [Millipore] to reach 50 pL. Amplification was

72
performed in a Mastercycler (Eppendorf) using the following program: 94°C for 1
min, followed by 30 cycles of 94°C for 45 sec, 60°C for 45 sec and 72°C for 45
sec, and a final elongation step of 72°C for 2 min. Products were viewed via
electrophoresis in a 1% agarose gel using 1X TBE, stained with ethidium
bromide and viewed under UV light in an Alphalmager (Alpha Innotech
Corporation). Concentration of DNA in each sample was determined through
spectrophotometry, and a series of standards were made ranging from 5000
ng/pL to 5 x 10'9ng/pL. These standards were used as templates in the real-time
PCR reactions to construct standard curves with known concentrations of DNA.
Total protein from the supernatants used to challenge S. aureus MN8 in
the real-time PCR assay were precipitated and analyzed through SDS-PAGE in
order to compare protein expression among these bacteria. The procedure was
identical to the protocol described previously for analyzing S. aureus protein
expression through SDS-PAGE.
2.6. Statistical Analysis

Statistical analysis was performed on the real-time PCR data using the
GraphPad Prism® 4 program. Gene expression of the various conditions was
compared to the control using one-way ANOVA analysis with a Dunnett’s multiple
comparison test. Changes in gene expression were considered significant with p
values <0.05. The standard error of the mean (SEM) for each condition tested
was displayed on the bar-plots.

CHAPTER 3

RESULTS
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3.1.DGGE versus 16S rRNA Sequencing by lllumina

The first step in this investigation was to identify the most effective
bacterial identification technique by directly comparing DGGE to 16S rRNA
sequencing by lllumina. A total of 22 vaginal samples were obtained from a
clinical study held in Tanzania, Africa. From these, 6 bacterial species were
detected across 6 healthy and 2 intermediate samples using the DGGE method
(Figure 3.1 A), as well as 6 species in 9 women with BV (Figure 3.1 B). The most
common organisms detected from this sample pool were L. iners and G.
vaginalis, while several DNA bands from the BV subset were matched with
uncultured species using the BLAST algorithm. Overall, 8 different species were
detected in this HIV-positive sample pool, whereas 16S rRNA sequencing by
lllumina detected 59 bacterial species in the same 22 samples (Figure 3.2). The
lowest abundance of the 8 species detected by DGGE was 11 %. The group of 8
species found through DGGE represented a subset from those detected by the
lllumina method.

75

21

50

54 63

Healthy

71

86

6

18

49

Intermediate

Figure 3.1 A. PCR amplicons of vaginal bacterial DNAfrom the African study of
women with healthy and intermediate vaginal status, as determined by Nugent
scoring and Amsel’s criteria. Extracted DNA was electrophoresed on a 30-50%
denaturing gradient gel. DNA bands are labeled as follows: cr= Lactobacillus
crispatus-, ga= L. gasseri; va= Gardnerella vaginalis-, in= L. iners; de= L.
delbrueckii sp. bulgaricus; an= Streptococcus anginosus.
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Figure 3.1 B. PCR amplicons of vaginal bacterial DNAfrom the African study of
women with intermediate and BV vaginal status, as determined by Nugent scoring
and Amsel’s criteria. DNA bands are labeled as follows: in= Lactobacillus iners\
un= uncultured organism; va= Gardnerella vaginalis', ha= Haemophilus influenzae;
am= Leptotrichia amnionii\ ag= Streptococcus agalactiae-, pr= Prevotella spp.;
amni= Prevotella amniotica.
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Prevotella melaninogenica
Streptococcus anginosus/mllleri
S. phocae/difficilis/porcinus
S. pneumoniae/oralis/
Sneathia sanguinegens parasanguinis/ infantis/mitis/
Leptotrichia
sangulnis/merlonls/
sanguinegens
oligofermentans
Atopobium vaginae
Peptostreptococcus anaerobios
Prevotella timonensis
Gerne!la sp. WAL
Dialister
Aggregatibacter aphrophitus/ segnis
propionicifaciens
Haemophilus segnis/quentini/
Lactobacillacea:
inftuenzae/paraphrophiius
Granulicatella/A eroco Gerne!la sanguinis/ haemolysans/
ecus/
morbillorum
A topobacter/Abiotrop
hia

Shewanella harveyi
Vibrio harveyi
Vibrio owensii/
rumoiensis/hepatarius/par
ahaemolyticus/natriegens
Nitrincota lacisaponensis
Citrobacter freundii
Serratia plymuthica/
marcescens/ entomophila
Photobacterium
rosenbergii

Illumina

DOGE

Figure 3.2. Venn diagram comparing bacterial species found through DGGE
versus lllumina sequencing. A total of 8 species in 22 clinical samples were
detected via DGGE, compared to 59 by the lllumina method. Figure adapted from
Gloor et at. (2010).
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3.2. Vaginal Microbiota of Pre-menopausal Women With and Without
Bacterial Vaginosis in London, ON

A clinical study was undertaken to collect vaginal samples and determine
the microbiomes of women with and without BV, and to look for the presence of
S. aureus in this population. A total of 34 pre-menopausal women were recruited
from London, ON. Of these, 11 were scored healthy, 10 intermediate and 13 BV
based upon Nugent score and vaginal pH (Figure 3.3). The mean age of
participants was 24.6 years. None of the subjects were diagnosed with AV nor
had a microbiome indicative of this condition.
The vaginal microbiota of participants were determined through 16S rRNA
sequencing by lllumina (Figure 3.4), and bacterial DNAfrom 21 participants was
successfully isolated and amplified for sequencing. These included samples from
subjects assigned to the healthy, intermediate and BV groups.
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Figure 3.3A. Gram-stained vaginal smear of a subject from London, ON with a
healthy microbiota (Nugent score 1-3), examined under oil immersion (x 1,000
magnification).
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Figure 3.3B. Gram-stained vaginal smear of a subject from London, ON
diagnosed with an intermediate microbiota (Nugent score 4-6), examined under
oil immersion (x 1,000 magnification).
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Figure 3.3C. Gram-stained vaginal smear of a subject from London, ON
diagnosed with Bacterial Vaginosis (Nugent score 7-10), examined under oil
immersion (x 1,000 magnification).
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The vaginal microbiota of healthy versus BV participants were very
distinct. The predominant species associated with healthy and intermediate
samples was L. crispatus (50.7% and 41.6%, respectively) followed by L. iners
(27.4% and 20.5%, respectively), with an average species abundance of 3.6
species per sample (Figure 3.4). Other bacterial species, including those
associated with BV, were present in relatively low abundance in these subjects.
Three outliers were present among these samples, having diversities of 11, 12
and 17 species per sample. One intermediate sample had no L. iners or L.
crispatus (>1% abundance), but instead consisted of L.jensenii, L.
gasseriljohnsonii and G. vaginalis of nearly equal abundances. Participants
assigned to the BV group, however, had a predominant Gardnerella vaginalis
population (average abundance of 49.7%), along with Leptotrichia amnionii
(3.9%) and Atopobium vaginae (3.7%). The BV samples had a higher bacterial
species diversity than healthy and intermediate, with an average of 10.5 species
per sample. Staphylococcus aureus was not detected in any of the 21
participants whose samples were sequenced by lllumina.

Microbiota fraction

83

Nugent Score
■
n
□
□
D
□
a
□
□
□
n
□
□

OTU_12-Prevotella amniotica
OTU_11 -Prevotella timonensis
OTU_10-Strep pneumoniae-mitts-sanguinis
OTU_9-Leptotrichia amnionii
OTU_8-uncuttured Veillonellaceae dialister
OTU_7-Lactobacillus gassen-johnsonii
OTU_6-Atopobium vaginae
OTU_5-Streptococcus thermophilus
OTU_4-Lactobacillus jensenii
OTU_3-Lacto Granulicatella-Aerococcus
OTU_2-Gard vaginalis
OTU_1-Lactobacillus mers
OTU_0-Lactobacillus cnspatus

□
■
□
□
■
□
■
a
■
□
Q
a
■

Sequences with <1% abundance
OTU_26-Porphyromonas uenonis
OTU_23-Streptococcus angmosus
OTU_22-uncultured unknown
O TU _21-Clostndiales BVAB1
OTU_20-Clostndiales BVAB2
OTU_19-Atopobium nmae
OTU_18-Sneathia sanguinegens
OTU_17-Streptococcus
OTU_16-Lactobacillus vaginalis
OTU_15-Dialisterpropionidfaciens
OTU_l4-Prevoteila bivia
OTU_13-Prevotella melaninogenica-verorahs

Figure 3.4. Vaginal microbiota of 21 subjects recruited from the clinical
study, as determined through 16S rRNA sequencing by lllumina. Vaginal
state determined via Nugent Scoring; score of 1-3 is healthy, 4-6 is
intermediate, and 7-10 is BV. Each column represents a participant, with
each colored bar representing a type of bacteria.
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3.3. Abundance of Staphylococcus aureus in Pregnant Women in
Toronto, ON

An additional dataset was studied from pregnant women, as that
population tends to have a higher incidence of AV. A total of 74 samples were
obtained from pregnant women at Mt. Sinai Hospital in Toronto, and these were
analysed by 16S rRNA sequencing by lllumina (Figure 3.5A). Most of the
samples in this population were dominated by L. iners and L. crispatus, with
others being composed of a complex population of several species. However,
some samples were outliers in that they were predominantly composed of a
single bacterial species other than lactobacilli. For instance, participant 44 had a
vaginal microbiome made up mostly of Mycobacteria. Reasons for these outliers
are unclear but may be due to the sampling method employed. The study from
which the samples were taken is double-blind and ongoing, and so the
prevalence of AV in these subjects cannot be determined. Staphylococcus spp.
were found in 13 of the 74 samples (17.6%) when applying a cut-off of >1%
abundance (Figure 3.5B). Due to the amplification and sequencing of the sixth
variable region (V6) of 16S rRNA, the Staphylococcus species detected were
separated into a S. aureus/haemolyticus group and S. epidermidis. The S.
aureus/haemolyticus group was detected in 11 of the 74 samples (14.9%), while
S. epidermidis was only present in 4 samples (5.4%). The highest relative
abundance of Staphylococcus spp. in a sample was 57.3% (Figure 3.5B,
Participant 32), and the average relative abundance in all samples containing
Staphylococcus spp. was 20.1%.
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M icrobiota Fraction

o

Panent ID Numbers
□
□
□
□
□
□
□

0TU_6 Lactobacillus rhamnosus/casei
0TU_5 Lactobacillus jensenii
0TU_4 Gammaproteobacteria
OTU_3 Lactobacillales
OTU_2 Garbrterella vaginalis
0TU_1 Lactobacillus crispatus
OTU_0 Lactobacillus iners

□
■
□
□
□
□
■

OTU_13 Atopobium vaginae
OTU_12 Lactobacillus fermentum
OTU_11 Staphylococcus
OTUJO Mycoplasma
OTU_9 Staphylococcus
OTUJS Enterobactehaceae
OTU_7 Lactobacillus gasseri/johnsonii

□ OTU_20 Veillonellaceae
■ OTUJ9 Lactobacillus vaginalis
□ OTUJS Streptococcus
M OTU_11 Prevotella timonensis
□ OTUJ6 Enterobactehaceae
■ OTUJ 5 Brevundimonas dimmuta
□ OTUJ4 Lactobacillus bulgancus

□
□
■
□
□

Sequences at < 1% abundance
OTU.25 Clostridiales BVAB1
OTU_24 Mycobacterium
OTU_23 Prevotella biva
OTU_22 Lactobacillus plantamm
m OTU_21 Roseomonas

Figure 3.5A. Illumina sequencing data depicting the vaginal microbiota of 74
pregnant women recruited in Toronto. Each column represents a subject, and
each colored bar within the columns represents a bacterial species.
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Figure 3.5B. Bacterial 16S rRNA lllumina sequencing data showing
Staphylococcus spp. present in 13 subjects recruited from Toronto, ON. Each
column represents a subject, and each colored bar within the columns
represents a bacterial species as listed in Figure 3.5A. Bars encased in red
depict staphylococci. Orange bars= S. aureus/haemolyticus group; grey bars=
S. epidermidis.
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3.4. Expression of tst in S. aureus in Women With and Without Bacterial
Vaginosis

In order to investigate the ability of the different vaginal environments to
influence the production of TSST-1, vaginal samples collected from non
pregnant, pre-menopausal subjects in London, ON were tested against cultures
of the reporter strain S. aureus MN8/pAmilux-Ptst to monitor activity of the tst
promoter (reflecting tst expression). Samples from all three vaginal states
(healthy, intermediate and BV) were tested in this luminescence assay, and
following 16 hours of growth, expression of tst in S. aureus was found to be
completely suppressed in all samples, as illustrated in Figure 3.6A. In contrast,
samples from two healthy participants were found to have no effect and only
some inhibition on tst expression (Figure 3.6B and 3.6C, respectively). Total
protein levels were determined via a bicinchoninic acid (BCA) assay in these two
samples, as well as in three samples demonstrating strong inhibition. This was
done to determine if the lack of suppression was due to an absence of protein in
these 2 samples. Results showed similar protein levels in all the samples,
regardless of anti-fsf activity. The expression of tst occurred primarily at the post
exponential phase (approximately 10 hours) except for the luminescence seen in
Figure 3.6B, in which expression began early and peaked at the mid-exponential
point (6 hours). Luminescence graphs of tst promoter activity in response to
samples from all other participants in the study are shown in Appendix 5.
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Figure 3.6A. Luminescence activity of S. aureus MN8 tst gene in response to
vaginal swab contents from 4 different women of varying vaginal health
(Participants 13-16) including healthy, intermediate and BV as determined through
Nugent scoring. Toxin production was suppressed in response to all health
groups. S=Staphylococcus aureus MN8; TM=Transport Medium, the medium in
which the swabs were preserved.

89

Figure 3.6B. Luminescence activity of S. aureus MN8 tst gene. Evidence of a lack
of fsf suppression from a healthy participant (Participant 7) during exponential
phase (5-8hr). S=Staphylococcus aureus MN8; TM=Transport Medium, the medium
in which the swabs were preserved.
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Figure 3.6C. Luminescence activity of S. aureus MN8 tst gene. Evidence of a lack
of tst suppression from a healthy participant (Participant 18) during stationary
phase (8-16hr). S=Staphylococcus aureus MN8; TM=Transport Medium, the
medium in which the swabs were preserved.
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3.5.TSST-1 Production in Response to Vaginal Bacteria Associated with
Bacterial Vaginosis, Aerobic Vaginitis and a Healthy Microbiota

In order to investigate whether specific species found in the different
vaginal microbiota samples have an influence on TSST-1 production, cultures of
S. aureus MN8 were grown with supernatants of AV-associated bacteria,
including S. agalactiae, E. coli and E. faecalis. The probiotic strain L. reuteri RC14 was also included, as this strain has been shown to suppress TSST-1
production (Li et al., 2011). Growth of S. aureus in these conditions was
monitored and grew to similar OD6oo values (Appendix 6). Proteins from these
cultures were precipitated and TSST-1 detected on a nitrocellulose membrane to
detect TSST-1 production semi-quantitatively in each of these conditions (Figure
3.7). The TSST-1 production in S. aureus MN8 varied depending on the
supernatant in which it was grown. Staphylococcus aureus, when challenged with
S. agalactiae, showed similar toxin levels to when it was grown with its own
supernatant. The supernatant from E. coli suppressed TSST-1 production only
slightly, while those from E. faecalis and L. reuteri RC-14 exhibited the greatest
suppression of toxin production. These findings warranted further investigation
into the influence of indigenous vaginal strains on TSST-1 production in S.
aureus.
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Figure 3.7. Western blot detecting TSST-1 production from S. aureus MN8
supernatants when challenged with supernatants of indicated bacteria.
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The supernatant challenge experiment was repeated and tst expression in
S. aureus MN8 was monitored by real-time PCR. Bacteria used to challenge S.
aureus were separated into 3 groups for data analysis: lactobacilli, AV-associated
and BV-associated (Table 2.5). Lactobacilli were found to significantly decrease
tst expression (Figure 3.8A). L. gasseri, L. jensenii and L. johnsonii decreased tst
expression by 76.15%, 82.67% and 67.15%, respectively (p<0.05). The probiotic
strains L. rhamnosus GR-1 and L. reuteri RC-14 decreased expression by
78.51% and 83.78%, respectively (p<0.05).
In general, the AV-associated bacteria increased tst expression. Secreted
products from S. agalactiae significantly increased tst expression by 509.15%
relative to S. aureus grown in BHI (p<0.05) (Figure 3.8B). E. faecalis and E.
faecium increased tst expression by 144.66% and 149.11%, respectively, while
E. co//decreased expression by 36.91%. These latter changes in gene
expression were not statistically significantly when compared to the control of S.
aureus grown in BHI.
Finally, the BV-associated organisms slightly increased tst expression. In
particular, P. bivia and A. vaginae increased expression by 190.58% and
334.06% (Figure 3.8C). This trend was not significantly different to the control of
S. aureus grown in half BHI and half VDMP.
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Challenger Bacteria
Figure 3.8A. Fold change in gene expression of tst in S. aureus MN8 in
response to supernatants from lactobacilli, as detected by real-time PCR.
1/2 BHI + 1/2 MRS = growth media used. * indicates p<0.05
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Figure 3.8B. Fold change in gene expression of tst in S. aureus MN8 in
response to supernatants from AV-associated aerobic organisms, as
detected by real-time PCR. BHI = growth media used. * indicates p<0.05
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Challenger Bacteria
Figure 3.8C. Fold change in gene expression of tst in S. aureus MN8 in
response to supernatants from BV-associated bacteria, as detected by
real-time PCR. 1/2 BHI + 1/2 VDMP = growth media used. VDMP=
Vaginally-Defined Medium + 0.5% Proteose Peptone.
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Total protein expression from these challenger bacteria varied greatly in
comparison to S. aureus as analyzed by SDS-PAGE (Figure 3.9). Among the
aerobes, E. faecium was found to have the most complex protein secretion
profile, while E. coli and S. agalactiae each showed high production of two
distinct proteins (Figure 3.9A). The lactobacilli demonstrated strong production of
certain proteins, seen at a mid-range size of approximately 50 kDa (Figure 3.9B).
In particular, L crispatus and L. gasseri showed a similar pattern of protein
expression except for an additional protein of high production noted in L. gasseri.
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Figure 3.9. Total protein expression of bacteria used to challenge S. aureus,
including aerobic bacteria (A) and anaerobic lactobacilli spp. (B), as
determined through SDS-PAGE.
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CHAPTER 4

DISCUSSION
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4.1. Induction and Inhibition of TSST-1 by Vaginal Bacteria
To our knowledge, this is the first report of indigenous vaginal bacteria
altering TSST-1 production in S. aureus. In particular, several species of
Lactobacillus significantly suppressed tst expression, including L. gasserl and L.
jensenii which are common vaginal residents, and L. johnsonli which is a gut
commensal occasionally found in the vagina. We have also confirmed anti-TSST1 activity from the vaginal probiotic strain L. reuteri RC-14, and showed that L.
rhamnosus GR-1, another vaginal probiotic strain, was also capable of
suppressing this toxin. Aerobic bacteria appeared to induce tst expression,
particularly S. agalactiae (group B Streptococcus: GBS) which significantly
induced expression by more than 5-fold. The BV-associated organisms tested, P.
bivia and A. vaginae, showed slight up-regulation of tst expression. These results
suggest that the vaginal microbiota can shape the virulence behavior of S.
aureus and that a loss of lactobacilli may increase an individual’s susceptibility to
developing menstrual-toxic shock syndrome (TSS).
It is of interest to consider potential causative factor(s) from the bacteria
responsible for altered tst expression. The pH of the challenger supernatants
were recorded and adjusted to match the pH of the S. aureus culture, therefore
excluding pH as a contributor to differential tst expression. The fact that the
bacteria-free culture supernatants altered toxin expression in the challenge
experiments suggests that the causative agent was a secretory compound rather
than a cell surface one.
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The expression of tst is under control of a two-component regulatory
system (TCRS), and so it is possible that quorum sensing (QS) played a role in
these reactions. Bacteria produce autoinducers (Als) in the form of oligopeptides
(Gram-positive bacteria) (Kleerebezem et al., 1997) and acylated homoserine
lactones (AHLs) (Gram-negative bacteria) (Fugua et al., 2001) that are detected
by the surrounding bacteria and regulate gene expression. In Gram-positive
bacteria, oligopeptides are detected by a membrane-bound histidine protein
kinase, which in turn activates an intracellular response regulator (Grebe &
Stock, 1999). This QS system in S. aureus has been extensively studied for
controlling the agr system in which tst expression is regulated (Cheung et al.,
2004).
Although most Als are limited to intra-species communication, the AI-2
group has been identified as a family of compounds capable of inter-species
signaling and is produced by both Gram-positive and Gram-negative bacteria
(Schauder et al., 2001). These compounds, synthesized by the LuxS enzyme
from the precursor 4,5-dihydro-2,3-pentanedione (DPD), have been shown to
alter virulence in E. coli and S. pyogenes (Lyon et al., 2001; Sperandio et al.,
1999). A study by Xu et al. (2006) found that luxS/AI-2 signalling in S.
epidermidis causes suppression of biofilm formation through reduced levels of
exopolysaccharide adhesins, which subsequently reduced virulence in a rat
model of infection. This signaling system also suppresses synthesis of capsular
polysaccharide synthesis (CPS) in S. aureus (Zhao et al., 2010). These effects of
AI-2 on Staphylococcus spp. resemble the phenotypic changes following

102
activation of the agr QS system, in which extracellular adhesins are downregulated and exotoxin production is increased. However, the luxS/AI-2 system
does not seem to have an effect on the agr system in S. aureus (Doherty et al.,
2006), and so these compounds may act through alternate signaling pathways to
affect toxin expression. These AI-2 compounds are thus possible causative
factors for the altered tst expression seen in our experiments.
A recent study found that the AI-2 compounds secreted by L reuteri RC-14
do not have an effect on tst expression (Li et al., 2011), which suggests that they
are likely not responsible for the suppression seen in response to lactobacilli.
However, AI-2 compounds secreted by the AV- and BV-associated bacteria
tested in the present study should be considered, as these compounds may vary
in structure depending on the producing organism and may have an influence on
TSST-1 production.
Future experiments could include challenging S. aureus with isolated AI-2
compounds and monitor tst expression. However, because these compounds
may vary in form depending on the producer strain and conditions, a single form
may misrepresent the bacterial members being tested. The most effective
approach would be to isolate the active AI-2 compounds from the challenger
supernatants and test against S. aureus (Bassler & Surette, 2008). First, a
genome survey would be conducted to determine the presence of the luxS gene
in the challenger species. This would then be followed by a bioassay to confirm
AI-2 activity from the supernatants, in which they would be added to the Vibrio
harveyi BB170 AI-2 reporter strain to detect activation of LuxS (Bassler et al.,
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1997). AI-2 activity would presumably occur as previous groups have confirmed
this in cell-free supernatants of E. coli and Streptococcus spp. (Merritt et at.,
2003; Wang et at., 2005). Mutant challenger bacterial strains lacking luxS could
then be used to challenge S. aureus and observe toxin production, although the
LuxS enzyme plays a role in the bacterial methyl cycle bacteria and so
phenotypic changes to S. aureus could not definitively be attributed to reduced
AI-2 levels from the challenger bacteria (De Keersmaecker et at., 2006; Winzer et
a/., 2002).
A possible explanation for the induced tst expression seen in response to
the aerobic bacterial challengers is that these organisms secreted an array of
compounds that mimicked the stationary phase of S. aureus. During stationary
phase, the agr system of S. aureus promotes the release of exotoxins due partly
to the build-up of Als (Dunman et al., 2001). Thus, since the aerobes in our study
were grown into stationary phase (12 hours) prior to supernatant collection,
introduction of S. aureus into these supernatants could have mimicked its own
stationary phase to varying degrees, resulting in a range of tst induction by these
bacteria. To determine the involvement of QS in the induction of this toxin, the
real-time PCR assay could be used to monitor genes associated with TCRSs,
including AgrAC, ArIRS and SrrAB. Linking these effects to QS would warrant
investigation into the various oligopeptides produced from the aerobes,
particularly S. agalactiae, E. faecium and E. faecalis.
The observation that S. agalactiae induces tst expression is particularly
interesting considering the seemingly-symbiotic relationship between this species
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and S. aureus. Multiple studies have found that S. agalactiae inhibits
Lactobacillus spp. and G. vaginalis without inhibiting S. aureus (Carson et al.,
1997; Chaisilwattana & Monif, 1995; Monif, 1999). One study also found that S.
aureus colonization was significantly associated with colonization by S.
agalactiae in a population of pregnant women (Chen et al., 2006). Our findings
thus illustrate further ways in which GBS promotes the virulence of S. aureus. In
the context of menstrual-TSS, women with AV who are colonized predominantly
with these two species might be at higher risk of developing menstrual-TSS;
elevated oxygen levels in the vagina would presumably induce TSST-1
production in S. aureus (Yarwood & Schlievert, 2000), and the presence of GBS
may further perpetuate toxin production.
It is interesting that the Lactobacillus species tested (L jensenli, L.
gasseri, L.johnsonii) suppressed tst expression, considering recent findings that
the vaginal probiotic strain L. reuteri RC-14 suppressed the toxin (Li et al., 2011).
This probiotic strain was included in the supernatant challenge experiment and its
anti-fsf effect was verified. Surprisingly, L. rhamnosus GR-1, another vaginal
probiotic strain, also suppressed the toxin. A study by Laughton etal. (2006)
found that this strain, in contrast to L. reuteri RC-14, was not able to suppress the
RNAIII-initiating P3 promoter. This suggests that the inhibitory effect on tst seen
by this strain was not due to inhibition of agr but perhaps from altered SarA
activity, as this protein family has been shown to bind and activate the tst
promoter directly and thus in an agr-independent pathway (Andrey et al., 2010).
Another regulatory system which seems to influence tst independently of the agr
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system is glucose catabolite repression, in which the carbon catabolite protein A
(CcpA) binds to catabolite-responsive elements (ere) in the tst promoter region
and prevents tef expression (Seidl et al., 2008). This represents the driving
mechanism linked with glucose-mediated repression of TSST-1 production
(Schlievert & Blomster, 1983). Thus, a possible cause of tst repression by L.
rhamnosus GR-1, as well as by the other Lactobacillus strains tested, is the
accumulation of glucose by the breakdown of carbohydrates in the culture media
used (de Man, Rogosa and Sharpe [MRS]). To test for this, a AccpA mutant
strain of S. aureus MN8 could be utilized in which a partial loss of inhibition could
be attributed to glucose repression.
The study by Li et al. (2011) isolated and identified two cyclic dipeptides,
cyclo(L-Tyr-L-Pro) and cyclo(L-Phe-L-Pro), from L. reuter/RC-14 responsible for
tst suppression. It would be worthwhile to screen the supernatants used in our
study for the expression of these compounds. Furthermore, steps could be taken
to deduce the compound(s) responsible, such as treating the supernatants with
proteinase-K and trypsin to test if the compound(s) are proteins. Treatment with
catalase would exclude hydrogen peroxide as the compound responsible,
although another group has previously ruled out this compound for the
suppression of the agr system (Laughton et al., 2006). Separation techniques
such as high-performance liquid chromatography (HPLC) could be utilized to
separate the supernatants into fractions, testing them for anti-tef activity.
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4.2. S. aureus TSST-1 Production in Aberrant States
We found that S. aureus colonization was no higher in women with BV
than with healthy women. However, it is still important to determine the nature of
TSST-1 production when in the vicinity of BV-associated bacteria. Mixed
conditions have been noted that resemble an overlap of BV and AV, which would
presumably have a higher likelihood of S. aureus being present (Donders et al.,
2002). As well, G. vaginalis and P. bivia, organisms associated with BV, have
been shown to increase in numbers during menses in healthy individuals, and so
it is important to predict how S. aureus would behave in response to these
fluctuations (Eschenbach et al., 2000; Srinivasan et al., 2010).
The contents of vaginal swabs from the subjects recruited in London were
introduced to cultures of the reporter strain S. aureus MN8/pAmilux-Ptst.
Monitoring the luminescence produced from this strain allowed us to identify the
nature of tst promoter activity (which reflects tst expression in the wild-type strain)
in real time during the growth of S. aureus. It was discovered that samples from
all three vaginal states in the sample pool (healthy, intermediate and BV) were
able to significantly suppress tst expression, which suggests that these states
have one or more compounds with anti-TSST-1 activity. The suppression seen in
samples from healthy women could have been due to suppressive effects from
lactobacilli, as the supernatant challenge assay of this study indicates inhibitory
factors secreted by these bacteria.
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The suppression of tst expression in response to BV samples was
surprising, as these samples had greatly reduced lactobacilli numbers as well as
pH’s greater than 4.5, with some as high as 6.0, which is more conducive to
TSST-1 production (Sarafian & Morse, 1987). However, the effect of pH would
likely be minimized as the transport medium used to preserve contents of the
swabs contained various buffering agents. Our results also suggest that BVassociated bacteria, as represented by A. vaginae and P. bivia, may induce
TSST-1 production. Levels of oxygen and carbon dioxide would not likely
contribute to suppression, as all samples were exposed to atmospheric
conditions during collection and preparation. Therefore, it is possible that host
derived factors were responsible for this effect, including immunological factors.
Zariffard et al. (2005) found that mucosal fluids from women with BV were
able to induce Toll-like receptor (TLR)-2 mRNA expression as well as IL-1(3 and
IL-6 production in peripheral-blood mononuclear cells. The TLR-2 recognizes
lipoteichoic acid from the cell wall of Gram-positive bacteria, has anti-S. aureus
activity, and responds to the bacteria through production of TNF-a, IL-1 (Band IL-6
(Knuefermann et al., 2004; Takeuchi et al., 2000). Thus, the BV samples from the
current study may have had elevated cytokine levels from TLR-2 stimulation
which altered tst promoter activity. Future experiments should utilize multiplex
immunoassays to detect and correlate cytokine levels in these clinical samples
with tst suppression.
Vaginal metabolites cannot be ruled out for the suppression effects. Future
studies could reveal the complex profile of metabolites being produced from both
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the microbiota and host tissue in samples from healthy women and those with
BV. For instance, samples with elevated glucose levels may be better able to
suppress tst suppression through the glucose catabolite repression system in S.
aureus. The quantity and abundance of this sugar can be determined through
commercial kits and high-throughput techniques, respectively, and correlated
with anti-TSST-1 activity.
4.3. Prevalence of S. aureus and Other Bacteria Associated with
Aberrant States
We also investigated the abundance of S. aureus in healthy and BV
premenopausal women. To determine the most appropriate method of bacterial
identification in vaginal samples, the traditional method of denaturing gradient gel
electrophoresis (DGGE), which has been used by our group previously and is
cost-effective, albeit laborious, was directly compared to 16S rRNA sequencing
by lllumina.
Analysis by DGGE was effective at detecting L. iners and G. vaginalis. These
were noted to be the two core members of the microbiota as determined through
16S lllumina sequencing (Hummelen et al., 2010). However, DGGE only
detected L. crispatus in one of the 22 samples, while sequencing by lllumina
found this species in all samples. The bacterial diversity in BV samples versus
healthy, as shown by 16S rRNA lllumina sequencing, was not apparent when
analyzing by DGGE; the average number of species identified in healthy,
intermediate and BV samples was 1.80, 1.80 and 1.89, respectively. This is in
contrast to previous DGGE studies of the vaginal microbiota, in which many more
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species were identified in BV samples (Heinemann & Reid, 2005; Vitali et al.,
2007). It is not clear why such diversity was not detected here.
Many of the sequenced DGGE amplicons contained numerous non
identifiable nucleotides which made it difficult to identify the corresponding
species. This problem was likely due to the close proximity of some bands on the
gel to one another, which can occur from two or more organisms with similar
amplicon sequences and melting behaviour of the DNA strands. This would then
lead to the excision of multiple bands and a mix of sequences.
Overall, DGGE was found to be a laborious process with limited
identification power. In contrast, 16S rRNA sequencing by lllumina was much
more effective at identifying the total bacterial composition. Consideration of
financial expenses also favored sequencing by lllumina, as processing of multiple
samples cost approximately $10/sample, while DGGE includes expenses
associated with an additional set of PCR reactions as well as dideoxy chain
termination sequencing. Therefore, comparison of these bacterial identification
techniques warranted the use of 16S rRNA sequencing by lllumina for the
remainder of the present study.
Vaginal bacterial communities from 21 premenopausal women in the
London, ON area were determined through 16S rRNA sequencing by lllumina.
Clinical examination determined that the vaginal condition was healthy in 9
subjects, while 7 had BV and 5 had an intermediate score based upon Nugent
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scoring. Women with AV were not recruited, as this condition is less well known
in the community and harder to identify as compared to BV.
Colonization by S. aureus was not evident in any of the women, which
might be attributed to the relatively small sample size. Parsonnet et at. (2005)
found S. aureus to be present vaginally in 9% of women. Based upon this finding,
recruitment of 11 or more healthy women would likely be necessary to yield the
detection of S. aureus. Interestingly, this species was also absent in the subjects
with an intermediate and BV state, despite the lack of Lactobacillus species
present in these samples and a concurrent reduction in anti-S. aureus activity
(Charlier et al., 2009; Ocana et al., 1999). Thus, there was no evidence that S.
aureus was more prevalent in women with BV versus without. The nature of
these bacteria being facultative anaerobes permits some growth in anaerobic
conditions, and some have been detected in samples from women with BV
(Devillard et al., 2005). However, bacterial growth would presumably be hindered
in the strict anaerobic conditions of BV as compared to the micro-aerobic healthy
environment.
This data set showed similar bacterial profiles to that seen in other studies,
in that L. iners, L. crlspatus and G. vaginalis made up the core members of the
microbiota (Hummelen et al., 2010; Zozaya-Hinchliffe et al., 2010). However, the
microbiota of pre-menopausal women varied from person to person, regardless
of health status. For instance, 4 of the 5 intermediate samples consisted primarily
of L. crispatus and L. iners, while the other was composed of L. jensenii, L.
gasseri/johnsonii and G. vaginalis. As well, although healthy vaginal samples
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typically contain less diverse populations compared to BV, very complex
populations were seen in two healthy samples (17 and 12 species per sample)
and one intermediate sample (11 species per sample) compared to the other
samples (average of 3.6 species per sample). Members of these populations
included A. vaginae, P. bivia and Streptococcus spp. Therefore, healthy women
into which S. aureus colonize may conceivably already be colonized with a
diverse population of bacteria, some of which may release compounds that
induce TSST-1 production.
Another data set was analysed which included 74 pregnant women in
Toronto, ON. Although the prevalence of AV in the general population is not well
understood, the condition is thought to be more common in pregnant women,
affecting approximately 10% of this population (Zodzika etai, 2011), and so S.
aureus was expected to be more prevalent in these subjects. In preparation for
sequencing by lllumina, the sixth variable region (V6) of the 16S rRNA gene was
chosen for amplification as this region is best for discriminating between different
Lactobacillus species, which were the bacteria of primary interest at the time that
this data set was initiated. As a result, some species of Staphylococcus could not
be discriminated between, and S. aureus and S. haemolyticus were grouped
together during analysis, while S. epidermidis was the other species identified.
Staphylococcus spp. were found in 13 of the 74 subjects (17.6%), and the
S. aureus/haemolyticus group in particular was present in 11 of the 74 subjects
(14.9%), which is higher than the reported 9% prevalence of S. aureus in healthy
premenopausal women. This latter difference may be because of the inclusion of
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S. haemolyticus which is known to be able to colonize the vagina (Iwantscheff et
al., 1985). Interestingly, this Staphylococcus group made up as much as 55%
abundance of the vaginal microbiota of some of the subjects. To our knowledge,
this is the first report identifying such Staphylococcus abundances relative to
other bacterial constituents using high-throughput sequencing. It would be
interesting to examine the abundance of S. aureus in healthy women compared
to the onset of menstrual-TSS, as it might document whether an abundance
threshold of S. aureus is a factor that predicates the condition. Such a study
would be difficult given the unpredictability of TSS.
Through analysis of sequenced vaginal samples of healthy, intermediate,
BV and AV-like women, S. aureus appeared to be more prevalent in AV-like
states in pregnant women. However, larger sample sizes are needed to confirm
this finding. In addition, diagnosis of AV should be established to make certain of
the correlation. This would necessitate microscopic diagnosis where the following
criteria are met: 1) absence of Gram-positive rods (lactobacilli) and replacement
with bacteria of other morphology, 2) presence of leukocytes, 3) more than 50%
of leukocytes being bloated with lysosomes (toxic leukocytes), 4) presence of
Gram-positive single or chained cocci, and 5) the presence of small, rounded
epithelial cells (parabasal epitheliocytes) (Donders et al., 2011). In addition, a
different region of the eubacterial 16S rRNA gene should be selected to
discriminate S. aureus from other related species.
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4.4. Future Directions
The present study reveals some insight into how the vaginal microbiota
may affect TSST-1 production by S. aureus. This opens up a range of new areas
of investigation into menstrual-TSS. The course of disease progression requires
colonization by S. aureus, TSST-1 production and translocation of the toxin
across the vaginal epithelium into the bloodstream. Future studies could include
examining how certain conditions affect translocation of TSST-1.
Translocation of TSST-1 across the vaginal epithelium into the blood is an
important step in TSS. Here, the superantigens (SAGs) elicit their pro
inflammatory effect on host immune cells. The toxin is recognized by epithelial
cells and crosses the cell layer via transcytosis (Brosnahan et ai, 2008). An
inflammatory process also plays a major contribution to TSST-1 translocation, as
TSST-1 and a-toxin from S. aureus trigger the release of pro-inflammatory
cytokines from the epithelial cells, damaging the integrity of the layer (Brosnahan
et ai, 2009; Peterson et ai, 2005). It is conceivable that the vaginal microbiota
can alter TSST-1 translocation, as many mucosal commensal bacteria are able
to affect the integrity of the mucosal epithelial layer. Several studies have shown
the ability of lactobacilli to improve mucosal epithelial integrity, through promoting
translocation of occludin to the tight junctions, activation of Toll-like receptor
(TLR)-2 signaling, and preventing epithelial damage produced by pro
inflammatory cytokines (Karczewski et ai, 2010; Resta-Lenert & Barrett, 2006;
Rosenfeldt et ai, 2004). Therefore, a translocation experiment could be
undertaken to investigate the effects of indigenous Lactobacillus spp. on TSST-1
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translocation across the vaginal cell line VK-2, using a Transwell membrane filter
system (Corning) to establish a cell monolayer. The effects of AV-associated
bacteria could also be investigated, as the pro-inflammatory nature of AV
suggests that these bacteria may cause epithelial layer damage and a significant
increase in TSST-1 translocation. Finally, investigating the required number of
TSST-1-producing colony-forming units to induce disease would allow for a more
targeted approach to prophylaxis. For example, S. aureus that co-aggregate with
lactobacilli on the epithelial cell surface may not produce much toxin, whereas in
the presence of GBS it may take fewer staphylococci to trigger disease.
Staphylococcus aureus often colonize tissues in the form of a biofilm,
consisting of a matrix of extracellular polymeric substance surrounding a
microbial population. These S. aureus biofilms have been found in the fluid of
menses and on the surface of used tampons (Veeh et al., 2003), and in vitro
studies have shown that these organisms attach well to tampon surfaces (Reid et
al., 1995). Given the number of bacterial species found in the vagina, it is likely
that S. aureus are in biofilms with other species (Donlan, 2001). In vitro testing
could be undertaken to assess the ability of S. aureus to co-aggregate with other
urogenital strains and form a biofilm. If certain mixed biofilms, for example with S.
agalactiae, provided a critical induction or stimulatory effect on S. aureus TSST-1
production, this might represent a risk factor for menstrual-TSS.
The influence of lactobacilli could also be tested against S. aureus
biofilms. Our group has previously shown that the probiotic strains L. reuteri RC14 and L. rhamnosus GR-1 are able to displace BV-associated biofilms made up
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of G. vaginalis and A. vaginae (McMillan et al., 2011; Saunders et al., 2007), and
to displace S. aureus from various polymer surfaces (Hawthorn & Reid, 1990;
Reid & Tieszer, 1994; Velraeds et al., 1998). These studies have shown that
biosurfactants in the supernatants of lactobacilli and viable whole cells can
reduce pathogen adhesion to surfaces and displace those that have attached. Of
interest for a future study would be to investigate changes in the expression of
genes necessary for biofilm formation in S. aureus, such as in the lytSR and
IrgAB operon (Sharma-Kuinkel et al., 2009) and the intercellular adhesion (ica)
locus (Cramton et al., 1999), which could all be monitored through real-time PCR.
Understanding the nature of S. aureus biofilms in the vagina would give a better
indication as to when an individual is at a higher risk of disease, as well as help
develop new methods to control toxin production.
4.5.Conciusions
Our findings collectively suggest that women with AV who use tampons
may be most susceptible to developing menstrual-TSS (Figure 4.1). This study
showed that bacteria associated with AV (Streptococcus agalactiae,
Enterococcus faecalis and E. faecium) directly increase TSST-1 production in S.
aureus, and that a depletion of lactobacilli could remove otherwise suppressive
effects on S. aureus. These microbial influences on TSST-1 production could
conceivably augment the risk of toxin production from elevated oxygen levels and
a neutral pH in the vagina of women with AV. Also, S. aureus would not only
attach to the surface epithelial cells and ECM, but also colonize the tampon
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fibers. Thus, in vitro testing is required to determine the virulence of S. aureus on
tampon fibers when exposed to these various AV-like conditions.
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Figure 4.1. Schematic representation of S. aureus (purple cocci) colonization in
an AV-environment, binding to the vaginal epithelial cells, ECM and tampon fibers.
These bacteria are co-colonized with aerobic organisms including E. coli (red
rods), S. agalactiae (green cocci) and Enterococcus spp. (blue cocci), of which the
latter two secrete currently unidentified compound(s) that induce TSST-1
production. The combination of these secreted compounds, elevated oxygen
levels, a neutral pH and a leaky vaginal epithelial layer induced by local
inflammation may provide the necessary conditions for menstrual-TSS to occur in
pre-menopausal women.
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The BV vaginal environment seems to suppress tst expression despite the
induction of this gene by Atopobium vaginae and Prevotella bivia. This suggests
that some women with BV may have an aberrant yet somehow protective
microbiota against TSS, but further research is required to explain this.
Aerobic vaginal environments are more often found in pregnant women,
including S. aureus and GBS colonization, yet this population which does not use
tampons does not have a higher rate of TSS, for reasons that remain unclear.
Post-partum women who use tampons, however, may be most susceptible to
menstrual-TSS, but reasons other than the tampon seem to be involved. For
instance, these women appear to have a higher partial pressure of oxygen (Hill et
al., 2005), perhaps due to increased oxygen diffusion into the expanded vagina
or post-partum haemorrhaging which occurs in 2-11% of deliveries (Gilbert et al.,
1987; Tamizian & Arulkumaran, 2001). Also, this group has a higher colonization
rate by S. aureus, as suggested in a study which found 17% of post-partum
women colonized versus 9% of all other premenopausal women (Linnemann et
al., 1982). Therefore, the use of probiotics to counter AV post-partum, especially
those colonized with GBS, may be an effective approach to further reduce the
rate of menstrual-TSS in our society.
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Title &Posilion Graduate Student, Study Coordinator
Department LHRI, Rm F3-127
Building &Street Address SJHC, 268 Grosvenor St
City, Province London, ON
Postal Code N6A4V2
Telephone
________ I
l______________________
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Email (required)
For security purposes please provide
your hospital, institute or UWO email
address whenever possible.

(or their records), resources or
staff at any of these sites?
If YES toany item, please note
that the UWOOffice of Research
Ethics will routinelyshare
information as to theethics
approval status and other ethicsrelated or conduct-of-research
issues of this submission withthe
LHRI Grants &Contracts Office.
In some instances if may be
necessary toalso informthe
LHSC/SJHC Privacy Office.

1.8

Type of research activity
Select all that apply

(check all th a t apply)

LHSC - Victoria Hospital - YES
LHSC - University Hospital - YES
LHSC - South Street Hospital - YES
LHSC - London Regional Cancer Program - YES
Children s Hospital of Western Ontario - YES
UWO Fowler Kennedy Clinic - YES
St. Joseph’s Health Care London- YES
Parkwood Hospital - YES
Regional Mental Health Care (London ) - YES
Regional Mental Health Care (St Thomas) - YES
Byron Family Medical Centre - YES
Victoria Family Medical Centre - YES
Chart or record review/ data collection
Biological specimen collection and /or use
Survey, interview, questionnaire, focus group
Physiological or psychological testing
Registering a data base/registry/specimen bank

X
X

XMiddles
ex
Other (specify) London
Health
Unit
Is this a student or resident protect? i.e. Is completion of this research a
YES
X
requirement for a course, degree or traininq/placement program?
NO
1 9b
If YES, please describe the course, degree or program (e g. name of course, Honours BA paper,
Masters or Ph.D. theses etc) and the student's role in the research (e.g. questionnaire design, data
collection, interviews, data analyses etc).
= > This study will be part of the thesis project for a Masters program in Microbiology and Immunology. The
student, Roderick MacPhee, is acting as Study Coordinator and will play a rote invarious aspects of the sludy,
including questionnaire design, participant recruitment and data analysis.
1.9a

1.10a Is this initiative funded?

YES
NO

X
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110b l If YES, identify source of funds and name of person towhomthe funds have been awarded.
Kimberly Clark Corporation, granted to Gregor Reid and John McCormick._______________________
1.11a Was this research and/or database/registryfoank initiated fromoutside UWO or
YES
the hospital or research institute? e g. a commercial sponsor; other health care
NO
centre, other researchers etc.
X
1.11b If YES, identify the external parties and describe the relationship with the local researchers. Note; that
research and databases/registries/banks sponsored and/or maintained by commercial sponsors maybe
required topay an ethics reviewfee. If theOffice of Research Ethics thinks this is necessary you will be
contacted for billing information.

Is there collaboration with a commercial sponsor or the possibility of
YES
X
commercialization?
NO
1.12b If YES, describe.
Study has been fundedby Kimberly Clark Corporation, Neenah, Wl. This clinical part is not likely lo lead to
anything commercial.____________________ '________________________________
1.12a

1.13a

REB A dm inistratio n Fee

The University requires an administrationfeetor industry funded protocols submittedfor ethical review.
Please select billing optionA) or B),
Note: It is ultimately the responsibility o f the local investigator to ensure the tee is paid. In the event the Officeo f
Research Ethics is not able to recover the fee in a timely manner from the party named below, an invoice will be
sent to the Local Principal investigator for payment. Failure on the part o f the Sponsor o r the Investigator to pay
the fee In a timely manner may result in the withholding o r withdrawal o f ethics approval
such time as the

unit/

matter is resolved.
A)

Th e fu nd s fo r th is stu d y w ill be adm inistered by Lawson Health Research
Ins titute (LHRI) Th e fe e w ill be paid from a LHRI research a c c o u n t
If N

0, please providecompletebilling informationbelowinpart *B".
B) The funds for this study will not be administered by LHRI. Send invoice to:
B ILLIN G IN FO R M A TIO N - C O M PLE TE A LL SECTIO NS

Company or Institution
Contact Person
Street Address
City
Country
Telephone Number
CONTRACT BJOR PROTOCOL REFERENCE NUMBER REQUIRED
To ensure the sponsor is able to match the invoice for the ethics
administration fee with the contract you must provide the contract
and/or protocol reference number.

Province /State
Postal Code
Fax

YES
NO

X
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If you feel that due to extenuating circumstances the REB fee should be waived or adjusted, provide a brief written
explanation to the Office of Research Ethics p rio r to the submission of this protocol. Include the following:
•

I ndicate how the fund ng will be used (budget)

•

Identity who will own the data or any intellectual property arising from the agreement

•

Indicate if there are any restrictions (e.g publication delays) imposed upon the investigator by the sponsor and if so.
what they are.
Do not assume that prior waivers or discounts wll also apply to this submission (Email tf)etch6@uwo.ca or
dgrafton@uwo,ca or write to Office of Research Ethics R o o t SSB 4180 UWO)___________________________________

1.13b

l C o n d itio n s fo r In d u s tr y F u n d e d R e s e a r c h

Investigators are reminded of the following requirements :
•

■

all agreements and contracts must be approved by the appropriate research administration office for their institution
pnor to starting the study (e.g. LHRI Clinical Research Office of Grants and Contracts; UWO Offices of Research
Development Services or Industry Liaison etc.);
contracts and agreements must not put undue limitations on an investigator's right to publish;

•

contracts and agreements must not prohibit a study investigator from informing research participants of any risks that
may arise during a study;

•

investigators and their staff are not permitted to accept finders tees' for subject recruitment, nor accept compensation
tor services rendered that is significantly greater than their normal wages or fees for time spent; and,

•

research related expenses should be covered by the project Sponsor or other research funds not by OHIP, the
participant's health insurance a the institution’s operating budget.
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C onflict o f In terest - G e n e r a l
This section to be completed for all submissions not just those funded by industry. Note also that this
declaration applies to aii co-investigators as well as the Principal Investigator.
Do any of the investigators or their immediate families have any proprietary interests in

YES

the product under study or the outcome of foe research inducing patents, trademarks,
NO

copyrights and licensing agreements?

1.15

C onflict o f In terest - In d u s try S ponsored Protocols O n ly

Notealso that this declaration applies to all co-investigators as well as the
Principal Investigator.

N0-j. pp!
_
ArmwusLC
YES

1.15a
1.15b
1.15c
1.15d
115e

1.16

X

NO

Are any of the investigators or their immediate families receiving any personal
remuneration (including investigator payments and recruitment incentives) fromindustry
sponsors for taking part in this investigation?
Is there any compensation for this study that is affected by the study outcome?
Do any of the investigators or their immediate families have equity interest in the
sponsoring company? (this does not include Mutual Funds)
Do any of the investigators or their immediate families receive payments of other sorts
fromthis sponsor (e.g. grants, compensation in the formof equipment or supplies,
retainers for ongoing consultation and honoraria)?
Are any of the investigators or their immediate families members of the sponsor s Board
of Directors (or comparable body!?

X
X
X
X
X

If YES toany of the above in 1.14 or 1.15 please describe the arrangement and discuss the
implications of a potential conflict of interest. If the conflict of interest cannot be eliminated, what the
conici is and howthat conflict is being managed should be disclosed in fie Letter of Information. The
document shouldexplain what additional protections have been put in place toprotect the study
subject.

=»

1.17

Does this submission involve the creation or approval ot formal and ongoing
databases, registries orspecimen banks?
This does not indude one-time data collection projects or the use of existing
data bases, registries or specimen banks._______________________

YES
NO

IF NO, GO TO SECTION 2

1.18

Describe what type of
approval you are seeking
with this application
(check all that are

Collection of local daia/specimens for lo c a lly m a in ta in e d
database/registryfoank
Collection of local data/specimens for o f f s ite
database/registryfoank

X
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Establishment of local database/registry/bank that will contain
______________________________ lo c a l d a ta o n ly
Establishment of a London-based multi-site
database/registry/bank that will contain data/specimens from
multiple sites (local and/or non-local). Non-local sites must obtain
REB approval fromtheir own institution prior tosubmitting data
Other (explain)

1.19

Indicate which of the
options best describe
this
database/registry/bank

1 20

Who owns thedatabase/ registry/ bank?
Who is responsible for ongoing data or specimen stewardship? E g. Is there a Management or
Steering Committee.? If so describe the membership, roleand responsibilities of the committee,

1.21a

Will data or specimens be made available to other researchers in the
YES
future?
NO
If YES, what is the process for determining who may access data/specimens for future research?

121b

NEWClinical database/reqistry that is also to be usedfor research
PRE-EXISTING Clinical database/registry thatwill nowalso be
used for research
NEW Research only database/reqistry/bank
PRE-EXISTING Research only database/registry/bank
Other (specify)

osi*
1.21c

If YES, will researchers who are grantedpermission toaccess the data or
YES
specimens in the future have access topersonal identifiable information?
NO
If YES, it must be made very clear in the Letter of Information/Consent formthat researchers in the future may
have access to identifiable data, if the database is maintained locally, the UWOHSREB must approve
subsequent uses of thedata when identifiable data is included.
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SECTION 2 PROJECT DESCRIPTION

Complete each section where indicated. Do not direct the reviewer to 'SEE ATTACHED1.Your protocol will be
RETURNED UNREVIEWED if the project description information is incomplete, illegible or improperly filled out.
21a

Provide a brief one or two sentence overview of the proposed research or database/registry/bank
describing the population and purpose e g Charts of patients less than 3 months of age presenting to
the CHWOEmergency Department with a rash wilt be reviewed to examine possirle seasonal
variations, eg. - Clinical data frombreast cancerpatients will be amalgamatedinto a provincial
database called BRCAData to facilitate assessment of clinical trial outcomes inbreast cancer patients
This ongoing database is located at Princess Margaret Hospital in Toronto and is ownedby OCRN.

=> S even vaginal sw ab s w ill be co lle cted from 20 prem enopausal w om en: 10 healthy w om en and 10
w ith b acterial vaginosis. T hese sw ab s w ill collectiv ely be used fo r assessin g the effects o f th e vaginal
m iero b io ta on to x ic sh ock sy n d ro m e to x in (T S S T -1 ) regulation in Staphylococcus aureus M N8.
21b

Provide KEYWORDS about
the research. (Max 5)

2.2

Background, Justification & Objectives and Hypotheses: Provide a clear statement of the purpose
and objectives of the research or database/registry/bank. (i.e. Why is the research being done or the
database established?) (1 page maximum- adhere topage limitations) References may be appended
to this section and need not heed the 1page maximum

Bacterial vaginosis, toxic shock, mierobiota

M en stru al-asso ciated to x ic sh o c k sy n d ro m e (T S S ) becam e prom inent in th e early 1980s
w h en a sig n ifican t n u m b er o f T S S c ases o c cu rre d in otherw ise healthy y o u n g w om en u sing high
ab so rb en c y tam p o n s (1). T h e stap h y lo co ccal su p eran tig en (S A g) T S S T -1 is b e lie v ed to be
resp o n sib le fo r essen tially all m en stru al-asso ciated T S S cases (2). T his is likely related to the
ap p aren t u n ique ab ility o f th is p a rticu la r S A g to cross m ucosal banners (3). A lthough th ere are key
h o st a n d en v iro n m en tal facto rs k n o w n to in flu en ce th e dev elo p m en t o f staphylococcal T S S ,
in clu d in g elevated p ro tein , C O 2 and O 2 , and neutral pH (4), there are essentially no m echanistic
stu d ies relatin g to h o w th e vaginal m ic ro b io ta influences the developm ent o f this po ten tially fatal
disease.
In th is study w e w ill ex am in e the m iero b io ta o f hum an vaginal sam ples in o rd er to correlate
reg u latio n o f TSST -1 p ro d u c tio n by S. aureus a n d presence o f p articu lar bacterial species.

Objective: T o ex am in e to ro le o f resid en t vaginal m icroorganism s in TSST -1 expression b y S.
aureus. V aginal sa m p le s w ill b e o b tained from 10 healthy, pre-m enopausal w om en and 10 w ith
bacterial vag in o sis as d e te rm in e d by N u g en t scoring. C ontents o f the sw ab s w ill be identified and
ex am in ed f o r th e ir ability to a ffe c t the expression o f TSST-1 to x in b y S. aureus M N 8.
H y p o th e sis: A “ h ealth y ” vag in al m icro eco lo g y w ill inhibit expression o f T SST -1 b y S. aureus.
w h ereas an im b alan ce in th e vag in al m icro eco lo g y w ill p rom ote increased expression o f T SST -1.
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P AGES

M e tho do logy - Describe the study design or data collection process and describe in detail what will be
done tothe participants and/or their data or specimens Investigators are encouraged touse flow
charts or diagrams in their descriptions. (2 page maximum - adhere to page limitations)__________

=>
In th is stu d y , sa m p le s fro m 2 0 p rem en o p au sal w o m en w ill be included in data analysis; 10
w ith b acterial v a g in o sis and a vag in al pH g reater titan 4.5, and 10 health y w o m en w ith a vag in al pH
less th an 4.5. It is ex p ected th at as m an y as th ree w o m en w ill need to be screen ed fo r every- w om an
that sa tisfie s the above c rite ria (e x p ec te d total o f 60 participants). Seven vaginal sw ab s w ill be
co llected from th e p o ste rio r fo rn ix o f the vaginal trac t o f each participant through th e use o f a
specu lu m . T hese sw ab s w ill be u se d (1 ) fo r th e diagnosis o f B V through N u g en t scoring, (2 )
id en tificatio n o f b acterial sp e c ie s p re sen t in the vagina, (3 ) co -cu ltu rin g w ith Staphylococcus aureus
M N 8 to a ssess effects o n to x ic sh o ck sy n d ro m e to x in (T S S T -1 ) reg u latio n , (4 ) isolation o f
lacto b aeilli to study effe c ts o f th ese sp e c ie s on T SST -1 transport across vaginal epithelial cells,
isolatio n o f (5) bacterial an d (6 ) v a g in a l ep ith elial cell m R N A f o r gene expression analysis, a n d (7 )
fo r m ea su re m e n t o f vag in al acid ity . S w abs w ill be stored o n ice fo r tran sp o rt to L H R I.
T h e vag in al m ic ro b io ta o f each particip an t w ill b e determ ined a s follow s. D N A w ill b e
isolated fro m on e sw ab from each p articip an t b y su spending th e sw ab in PB S , fo llo w ed by D N A
ex tra ctio n u sin g a co m m ercial D N A ex tractio n kit. E ubacterial prim ers w ill be u se d fo r P C R
am p lificatio n o f 16S rR N A g enes a n d th e PC R p ro d u cts w ill be separated by D en atu rin g G rad ien t
G el E le ctro p h o re sis (D G G B X 5). A fte r stain in g an d v isu alizatio n o f th e g els, D G G E frag m en ts w ill
be ex cised fro m the g e l, th e D N A co n ta in ed w ith in the fragm ents w ill be re-am p lified b y P C R , and
th e resu ltan t P C R p ro d u cts w ill be pu rified a n d sequenced fo r identification o f b acterial species
rep resen ted b y each fra g m e n t
M icro o rg an ism s w ill b e iso lated from a sw ab front each p articip an t a n d added to S. aureus
M N 8 cultures. E x p ressio n o f T SST -1 in each c u ltu re w ill be determ ined b y W estern h n m u n o b lo ttin g
u sing a T S S T -1 -sp e c ific an tib o d y , a n d b y q u antitative R T -PC R analysts o f tran scrip tio n al levels o f
tut (en co d in g T S S T -1 ).
L iteratu re C ited
1.
2.
3.

4.
5.

2.4a

M c C o rm ic k , J . K ., J . M . Y a rw o o d , am ! P. \ L S c h lie v e rt. 2001. T oxic sh o c k sy n d ro m e
an d bacterial su p eran tig en s: an update. A nnu. R ev. M icrobiol. 55:77-104,
B e rg d o ll, M . S ., a n d P . M . S c h lie v e rt. 1984. T o x ic-sh o ck syndrom e toxin. L an c et 11:691.
S c h lie v e rt, P . M ., L . M . J a b lo n s k i, M . R o g g ian i, I. S a d le r, S. C a U a n tin e , D . T . M itc h e ll,
D . I I . O h lc n d o r f, a n d G . A . B o h a ch . 2000. Pyrogenic to x in su p eran tig en site sp ecificity in
to x ic s h o c k sy n d ro m e an d fo o d p o iso n in g in anim als. In fe c t Irnm un. 68:3630-4.
M c C o rm ic k , J . K ., J . M . Y a rw o o d , a n d P . M . S c h lie v e rt 2001. T oxic sh o ck sy n d ro m e
and b a cteria l superantigens: an update. A nnu R ev M icrobiol 55:77-104.
B u r to n , J . P ., a n d G . R e id . 2 002. E valuation o f the bacterial vaginal flo ra o f 20
postm en o p au sal w o m e n by d irect (N u g en t sco re) and m o lecu lar (po ly m erase ch ain re ac tio n
an d d e n atu rin g g radient gel electro p h o resis) techniques. J. Infect. Dis. 186:1770-80.

Will any testing using an xray, CT, MRI or ultrasoundbe done?

YES
NO

X
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If YES provide a complete description of the testing and describe the exposure and give an
assessment of risk.
• Ifan MRI is being used UWO HSRE B wording MUST be included in the InformedConsent
documentation. - see HSREB Guidelines 2-G-ÛQ04 (formerly Appendix 3)
•

http://w w w .uw o.ca/researcW ethics/m ed/hsreb-guidellnes.hbn

• If radiological testing or therapy (including Xray, CT, MRI, ultrasound etc) is being used,
researchers may find the following website a useful resource in determining the appropriate
language for Informed Consent documentation toexplain these procedures and their risks to
participants http://w w w .rad lolo gyinfo .org/________________________________ _____________

2.5a

N um ber o f local subjects o r records

For databases/regislries indicate anticipated number of subjects from th is centre or give
approximate numbers tobe included each year.
Total num ber o f su bje cts o r records.

For databases/regislries indicate anticipated number of subjects inentire
datab ase /re gistry /ban k or give approximate numbers to be included each year .

60
60

Num ber o f sites or centres participating.

2.5b

If a fo rm a l sam ple size calculation
give a rationale for the proposed number of subjects; charts or records tobe reviewed; or
specimens collected.
Justify th e sam ple size an d /o r provide sam ple size calculation.
was n o t used

=» Due tothe specificity of pH values included in the inclusion criteria, it is predicted that vaginal swabs from
only 1 in every 3 participants will be eligible for further analysis. Therefore, recruitment of 60 participants should
fulfill the study of vaginal microbiota from20 women.

S E C T IO N 3 R ESEA R C H PA R TIC IPA N TS

3.1a

Will Ihe study, database/registry/bank involve data or samples from males
MALES
and females?
FEMALES
X
31b
If NO, explain why only one gender is being selected, (e q condition under study is gender sDecific)
=*• Only females will be studied because we are looking at differences of thevaginal flora
3.2

What is the age range of the participants who will participate in
the research or fromwhom the data or specimens are obtained?

3.3

Participant Inclusion Criteria: Premenopausal females aged 18-40.

LOWER AGE LIMIT
UPPER AGE LIMIT

18
40

153

m m a ftxtt - UW O HSREB D ELEG ATED REVIEW (O C T 2008)

34

CO N FID EN TIAL___________________

PAGE 11

Participant Exclu sio n Criteria (if applicable).

=* Pregnant; sexually transmitted infection (specifically, gonorrhoea or chlamydia); abnormal renal function or
pyelonephritis; are receiving prednisone or immunosuppressive drugs, are receiving treatment for any
urogenital infection or are taking any antimicrobial therapy: have a personal history of known or suspected
estrogen-dependent neoplasia such as breast or endometrial cancer; have undiagnosed abnormal vaginal
bleeding; had sexual intercourse within the past 48 hours; have taken any acidophilus' or probiotic health food
supplements in the past 48 hours; are menstruating at time of clinical visit; had any urogenital infections in the
past 6 months.
3 5a
35b

3.6
36a
3.6b
3.6c

Will lhe participants be current or onaoina hospital or clinic patients or clients?

YES
NO
X
If YES, list all procedures, tests, drugs etc. utilized for the purpose of this study which are n o t p a r t o f
o r d in a r ily a c c e p te d ca re of the patient. If additional or extended hospitalization or outpatient visits
are required include the number of days orvisits.

NOT APPLICABLE
STUDY DOES NOT INVOLVE
PATIENTS
Are any standard therapies or diagnostic procedures to be withheld dunng the
YES
course of the study?
NO
X
Will management or treatment of the participant's condition be prolonged or
YES
delayed because of the research? Will a placebo be used in lieu of standard care?
NO
X
If YES toany of the above, discuss the potential risks and benefits to the particpants and provide a
rationale why standard care must be withheldor delayed
D elays or w ithholding o f standard care

=t>

3.7

D eception o r partial disclosure

3.7a

This section refers to instances of deliberate deceptionor the withholding of key
information that may influence a participant's performance or responses.
Do any of the procedures in this study include the use of this type of deception
or partial disclosure of information toparticipants?
If YES, provide a rationale for the planned deception or partial disclosure.

3.7b
=£*
3.7c

|3 8a

YES
NO

X

If YES, describe the procedures for a) debriefing the participants and b) giving thema second
opportunity to consent toparticipateafter debriefing. If debriefing and reconsent are not viable options
please explain.
|Will the participants be compensated or reimbursed for their time, expenses

| YES [

X
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and/or contribution tothe research?
| NO
If YES, provide details. Specify the amount, what the compensation or reimbursement is for, and how
payment will be determined for participants who do not complete the study.
This information must be included in the Information/Consent documentation. At a minimum,
researchers are strongly urged tocover parking and other incidental costs if participants are required
togo tothe hospital outside of normal appointments.

Participants will receive S50 for parking and travel tothe dinic.

SEC T IO N 4 B IO L O G IC A L S P E C IM E N S fe.o. b lo o d , tissue, m uscle biopsies o r tu m o r sam ples

41a

Are biological specimens (e.g. blood, tissue, muscle biopsies or tumor samples)
tobe taken or analyzed for the purposes ofthis research protocol?
41b
Are biological specimens being collected for future genetic testing or other
unspecified testing or studies?
If YES to either 4.1a or 4.1b complete the balance of this section.
If NO to both 4.1a and 4,1b go Section 5.________________

YES
NO
YES
NO

X

X

4.2a

Describe facilities and procedures toprotect the p h y s ic a l comfort and safety of the participants from
whomsamples will be taken. If specimens have been collected previously and stored, indicate “Not
Applicable”. In the case of invasive sampling e.g. taking blood, biopsies indicate who will take the
sample and give their qualifications todo so.
Not
=>The family doctor or a nurse will collect the samples in the confines andprivacy of a
treatment room
applicable
4.3a

Describe what specimens will be taken and what they will be used for.
In the case of blood samples also provide the totaI amount of blood that will be taken
= > V aginal sw abs. Swabs will first be analyzed for diagnosis of BV or a healthy vaginal microbiota using
Nugent scoring. Another swab will be used todetermine pHof vaginal fluid. Contents of the swabs will be
applied in a blinded fashion to S. a u reus MN8cultures, andboth protein and transcriptional levels of this toxic
shock toxin will be examined in S aureus. The microbiota ofthe swabs will be identified by 16s rRNA denatunng
gradient gel electrophoresis (DGGE). In this way, we will determine any correlation between an aberrant aerobic
or anaerobic microbiota and increased expression of TSST-1, as well as whether a healthyvaginal sample with
predominant laciobadlli content, is able to inhibit TSST-1. One swab will also be used for the collection of
lactobacilii speries tostudy the effect of these bacteria on the transport of the TSST-1 toxin across vaginal
epithelial cells. Two other swabs will be used for the isolation of bacterial and vaginal epithelial cell mRNA for
analysis of gene expression. Data collected fromthese swabs will thus expand upon the activity of these
bacteria and vaginal epithelial cells, and howthis activity may influence the regulation of TSST-1 production by
S ta p h y lo c o c c u s a u re u s MN8.
4.3b FExplain who will control or own the specimens?
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=*> Dr. Reid will control the specimens until the experiments have been performed.
4 3c [ Explain howand where the specimens will be stored.
=» The specimens will only be stored in the fridge for a day until processing. Bacterial DNA will be used for gel
electrophoresis study.
4.3d Describe how long the specimens will be retained and howthey will be destroyed.
■ The swabs will be destroyed within one week of collection as per standard waste procedures in the hospital.

4.4a

44b

What was the original purpose or use of the
tissue or specimens?

Collected specifically for research purposes X

Originally collected for diagnostic purposes
No purpose or use - unwanted or discarded
tissue or biomaterials
The subsequent use of tissue or biomaterials (except blood} orig inally collected fo r diagnostic
purposes must, be approvedby the Department of Pathology Tissue Use Committee prior to
submission tothe HSREB and a copy of their approval appended tothis form. If the Tissue Committee
approval is not available at the time of submission to the HSREB, ethics approval will be withheld until
a copy of Tissue Committee approval/registration is received.
Tissue Use Committee approval
Not applicable X
Pendinq
Approval attached

S EC T IO N 5 D A TA C O LLECTIO N

51

Are any data, other than biological specimens, tobe collected? e g. test results,
surveys, questionnaires, hospital chart information etc.

YES
NO

X

If YES complete the balance of this section - If NO go to Section 6
5.2

What is the
source of that
data?

Patient HOSPITAL chart or clinical record
Other HOSPITAL departmental records
eg. Pharmacy, Physiotherapy, Laboratory
Directly from research participant or other informant
NON-HOSPITAL clinician records e q. Family Physician office
NON-HOSPITAL laboratories or treatment sites e g. physiotherapy
clinic, laboratory
Departmental or clinic (clinical) database
Other (specify)

X
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List all data collection instruments and forms tobe used in this research, e.g. Chad abstraction
sheets, questionnaires, surveys, interviewoutlines etc. If there are no forms, you must provide a
comprehensive list of data to be collectedor topics to be covered.
Do not insert questionnaires etc into thebody of this applications; append a copy of all forms at the
end this application.
Questionnaire- Appendix C

S EC T IO N 6 RISKS A N D B E N E F ITS O F T H E R ESEARCH

g^

RISKS, H A R P S & D IS C O M FO R T S : Discuss the risks of the proposed research and/or
databaseiregistry/bank. Even though patients may notbe involved directly as inthe case of records
reviewor previously collected specimens, it is important, in addition tophysical harms, toconsider
possible psychological, emotional, social and economic harms and stressors and intrusions on pnvacy.

=*» T here w ill b e n o risk o r h a rm to particip an ts, although th ey m ay ex perience so m e d iscom fort
a sso ciated w ith co lle ctio n o f vag in al sw abs. A ny su ch discom fort w ill be m inim al and f o r a short
p erio d o f tim e.
______
____________________________________________________________

gj

B ENEFITS: Discuss any possible direct benefits to the research participants as a result of their
participation in the study. Please note that monetary compensation is not considered a benefit. If no
direct benefits are apparent, discuss possible benefits tosociety at large or to thepatient/participant
population being studied.
_____ _

*► T oxic sh o ck sy n d ro m e still k ilts a n d afflicts a considerable n u m b er o f people, m ain ly w om en,
each year. T he subjects w ill h a v e th e satisfactio n o f k n ow ing th a t th e ir p ro vision o f sa m p le s could
h e lp identify n e w m eth o d s to c o n tro l an d prev en t this condition.

6.3

The TOPS requires that researchers propose a continuing
reviewprocess appropriate for the risk of this submission. The
higher the risk the more frequent the review. P lease indicate
yo u r reco m m end ation a s to th e freq u en cy o f the R EB’s

At a minimum, all protocols continuing past
12 months will require the completion of the REB’s Surveillance
Report Form annually.

continuin g review.

ANNUAL (default)

X

EVERY 6 MONTHS
EVERY 3 MONTHS
EVERY MONTH

SEC T IO N 7 PR IVA C Y & C O N F ID E N T IA L IT Y ISSUES

LHSC and SJHC require that all persons accessing patient information complete the hospital Privacy
& Confidentiality Education Program. Contact the LHSC-SJHC Privacy Office for more information.
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If research data are lost, stolen or accessed inappropriately, it must be reported to the HSREB
immediately. If the data relate to hospital patients or records, a report must also be made to the
hospital's Privacy Office.

If any are to be collected,
indicate which will be re ta in e d
(upon stu d y com pletion) with
the research data set or
biological specimen once data
or biological specimen collection
is complete?

7.1b

Researcher« may find it helpful to consult the CIHR Best
Practices for Protecting Privacy in Health Research.

R etained

Indicate if any of the following
will be
c o lle c te d for research purposes
during the course of the
research. (Excluding the
consent formwhich will contain
the participant's name)
personal id entifiers

Collected

7.1a

No personal identifiers X

X

http:0wwK.cihNrscflceafefZS1S8.html

Full or Partial Name or Initials
Location or Contact info:
address, phone, postal code etc
Full or Partial Dale of Birth or Death
Personal Numbers: e g. OHIP Health Card, SIN
Institutional / Hospital Chart or Record #

Facilities and service providers
Indicate “Retained" if therewill
be a Master list kept after data
collection is complete that links
Other personal identifiers(specify)
participant identifiers todeidentifieddata.
IF ANY OF THE ABOVE IDENTIFIERS WILL BE C O LLE CTE D give the level of detail tobe collected.
E.g. full name or initials only; full date of birth or year only: full postal address or 3 digit postal code;
names of service providers or type of institution onlyetc.

* * S am p les w ill b e n u m b e r co ded b y p harm acy a t St. Jo s e p h ’s H ealth C entre an d no inv estig ato r will
be p riv y lo th e inform ation. T he n u rse o r phy sician co llectin g th e sw ab s w ill place the sw ab s in p re 
m ark e d v ials ( 1 ,2 , 3 , 4 . . .). T h e receiv in g tech n ician w ill n o t k n o w th e n am e o f the su b ject n o r i f she
is h e alth y o r has B V . O f n o te , it is p ossible th at th e re ce iv in g tec h n ician w ill have a good id ea w hich
sa m p le is fro m a B V su b ject (b a sed upon ex p erim en tatio n ), b ut th is can n o t in flu en ce the ultim ate
resu lts as th ese c o n sist o f sim p ly d o c u m en tin g w h ic h bacteria are present, a n d how S aureus reacts lo
th e flora.
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IF ANY OF THE ABOVE IDENTIFIERS WILL BE C O LLE CTE D provide a comprehensive rationale
explaining why it is necessary tocollect this information.
IF ANY OF THE ABOVE IDENTIFIERS WILL BE RE TA IN E D once data collection is complete provide
a comprehensive rationale explaining why it is necessary toretain this information. (Including the
retention of master lists that link participant identifiers with de-identified data.)
Acceptable reasons will generally be limited tothe following purpose and investigators will need to
defend their reasons for collecting and/or retaining identifiers and howthe identifiers will be used to
achieve the stated purpose.
• Contact or linkage for followup or ongoing data collection
• Provide data for clinical monitoring of the participant
• Enable data tobe withdrawn fromdata set if participant withdraws consent
• Return individual results toparticipant
• Conduct a data linkage with a high degree of accuracy
Do not just copy one of the above reasons into the box below. Investigators must, in their own words,
explain fully and defend their reasons for collecting and/or retaining identifiers and explain howthe
identifiers will be used to achieve the stated purpose.

=>

7.2

=>

7.3

In addition tothe UWO HSREB, identify all agencies or individuals other than the local research team
who, for m onitoring o r au diting purposes, may requireaccess to identifiable or confidential data
collected for this research or database/registry/bank, nowor in the future, e g. the Sponsor(s).CRO’s,
regulatory agencies such as Health Canada or the FDA etc.
Include the following sentence into all recruitment informed consent materials where the participants
identity is known and access to the records or follow upby the HSREB is possible.
"Representatives of The University of Western Ontario Health Sciences Research Ethics Board may
contact you or require access toyour study-related records to monitor foe conduct of the research."
None

Describe the procedures tobe used for preserving the confidentiality of data or specimens both during
the data or specimen collection and in the release of thefindings, e g. all identifiers removed once data
collected, data coded by unique identifiers with master list held separate fromdata etc. If a device has
a serial or code number that will allow the sponsor toidentify individual patients this shouldbe noted in
the Letter of Information.

159

J^OÌIM 21*002 • UW O HSREB D ELEGATED REVIEW (O C T 2008)

7.4a

CO N FID EN TIAL

PAGE 17

Will anyone other than employees, clinical staff or students of the institution where
the patients' original records or samples are located, approach participants or have
direct access toa subject or their records for purposes of collecting data or
conducting this research?

YES
NO X

7.4b

If YES indicate who these people are, what their role is, why they need access and what safeguards
have been instituted toensure they adhere toacceptable security practices and maintain confidentiality.

75a

Indicate which of the
following security
measures will be/has
been undertaken to
protect the data and
records

(check all that apply)
All hospital and research staff accessing patient information have
completed the hospital Privacy & Confidentiality Education Program

Data will be encrypted
Data will be password protected
X
Data will be stored on a hospital or other institutional network drive that
X
has firewalls and security measures in place
Hard copy records will be stored in a locked cabinet in a secure location
Access torecords and data limited toauthorized persons
X
All identifiers tobe femoved once data collected/verified
Master list linking data with identifiers stored separately fromdata.
Consultation with hospital Privacy Office or LHRI Research Office re
privacy and security issues
7.5b Describe these measures in more detail.
=j> No subject names will be used in any samples. Thus, there will be no confidentiality or privacy issues. All
electronic data will be kept on a password-protected computer in a locked laboratory and all paper files will
be kept in a locked filing cabinet ina locked office.

7.6

Indicate howlong the specimens and/or data will be retained and if not being kept indefinitely, describe
the method of disposal or destruction__________________________ _______________

The specimens will be destroyed upon processing.
7.7a

7.7b

Are participant data or biological specimens being sent or taken off-site toa
sponsor, co-investigator or central data collection site or registry?
MBa formal contracf or data or material transfer agreement must be in place
between the local institution and the recipient before data or specimens are
sent.
Will data be taken off site for analyses? E g. In the case of patient information is
lhere plans for the researcher to conduct analyses away from foe site? E.g. at
home?

YES

X

NO
YES
NO

X
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If YES to either 7.7a or 7.7b complete the balance of this section.
If NO go to Section 8,
78a

Will personal identifiers be included with the data or specimens sent or taken off

YES

site?

7.8b

78c

7.9d

Note Data and specimens that leave the site should not include the patient's name
or other identifiers unless there is a compelling reason. Data that includes
identifiable personal health information MUST be encrypted before being sent or
NO X
taken off site or utilized via secure remote access. Master lists must be stored
separately fromthe data. E g data files and the master list should not be stored on
the same portable device.
If YES, indicatewhich, if any, of
Full or Partial Name or Initials
these participant identifiers will be
Contact info: address, phone, postal code etc
included with the data or specimens
Date of Birth or Death
sent off-site?
Personal Numbers e.q. OHIP Health Card. SIN
Institutional / Hospital Chart or Record#
IF ANY OF THE ABOVE IDENTIFIERS WILL BE S E N T O R TA K E N OFF-SfTE provide a
comprehensive rationale explaining why it is necessary for this information togo off-site. Acceptable
reasons will generally be limited to the following purpose and investigators will need to defendtheir
reasons for sending identifiers off-site and howthey will be used to achieve the purposestated
• Contact or linkage for followup or ongoing data collection
• Provide data for clinical monitoring of the participant
♦ Enable data to be withdrawn fromdata set if participant withdraws consent
♦ Return individual results toparticipant
* Conduct a data linkage with a high degree of accuracy
• Data analyses
Do notjust copy one of the above reasons into the box below. Investigators must defendtheir reasons
for collecting andfor retaining identifiers and explain howthe identifiers will be used toachieve the
stated purpose.

If NO, will there be a code or identifiers
No personal identifiers sent/iaken off-site but data
thatallow linkage of the data and/or
andfor specimens are coded and linkage is possible. X
specimens back to the study and/or the Data and/or specimens completely de-identified and
research participant?
no linkage is maintained.
7.9e
If a LINKAGE IS POSSIBLE describe howthe data and/or specimens are to be coded toallow the
linkage and who will retain a master list linking participants and their date.
Note that in most instances the master list should remain in a secure location at the local site.
=> Each participant will be assigned a participant ID number which will be placed on the consent form of each
participant. These consent forms will act as the only linkbetween participant name and ID, and will be stored
securely with the administrative assistant of the local site. These files will not be accessible to the local or off-site
investigators. All samples, including those sent off-site, will only contain the ID number.
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Indicate which of the
following security
measures will befhas
been undertaken to
protect the data and
records

(o c t

2000

c o n f id e n t ia l ____________________________________ p a g e

19

(check all th at apply)

Data will be encrypted
Data will be password protected
Data will be de-identified
Data will be shipped by courier or other bonded shippinq method
Data will be personally delivered by researcher or research staff or
picked upby co-investigator or sponsor
All identifiers tobe removedprior to shippinq
Master list linking data with identifiers retained at local site.
Data sent by fax toa secure location

X
X

710

If YES toeither 7 7a or 7,7b, indicate w h ere data, records or specimens are sent or taken Be as
specific as possible.
«=» A vaginal swab fromeach participant will be smeared on a glass slide, which will then be delivered to the
Microbiology Lab of the London Laboratory Services Group, located at Victoria Hospital of the London Health
Sciences Centre, for the purpose of BV diagnosis.
711

If YES, describe ho w data or specimens are sent or taken off-site or accessed from off-site? (E.g.
hard copy, fax, electronic transmission email/web site, portable media devices, secure remote access,
courier etc.) and describe transmission safeguards and security measures i.e. Are data encrypted
prior totransmission? Ifyes describe level of encryption? Physical security (private faxes, shipping of
disks etc)?
Note that data containing identifiable personal health information MUST be encrypted toan appropriate
level.
=> The glass slides smeared with a vaginal swabwill be delivered personally by the research investigator to
Victoria Hospital,
7,12

If YES, Describe theo ff-s ite procedures for securing andstoring written records, videotapes,
computer discs, recordings and questionnaires, data and specimens________________ __
=> The Microbiology laboratory at Victoria Hospital will receive only theglass slides with participant ID, and
these slides will be stored only until analysis, after which they will be disposed. Staff at this site will followtheir
local procedures for safe storage and disposal of specimen.
7 13

If YES, indicate howlong the data or specimens will be retainedoff-site and describe the methodof
disposal if data or specimens are not returned tothe local site or not retained indefinitely
=*The glass slides will be retained at the Microbiology laboratory only until analysis is performed. The glass
slides will then be disposed of under proper disposal procedures established at this laboratory
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SEC T IO N 8 PA R TIC IPA N T R EC R U ITM E N T & C O N S E N T PR O C ESS
D isclaim er: The Review Board does noi assess the legal validity of the consent form nor does it provide any
other legal advice.________________________________________________________

81a

Will potential participants, or people associated with them, be contacted directly
YES
X
tocollect data fromthemor recruit themto the study?
NO
8.1b
If YES, identify who will be contacting the potential participants (andthe others) torecruit themand
howit will be done. I f y o u a n sw e r *y e s ’ to th is se ctio n , ensure that you submit a letter of information
with your study.
In the case of patients, initial contact must be made by a member of the patient s health care team,
circle of care, or someone the patient wouldexpect to have relevant information about themand their
medical problems.
In the case where others such as teachers or family members are asked togive information about the
study participant, the participant's permission is usually required for the other person to release the
information.
=*> Dr. Jo-Anne Hammondwill recruit subjects from her patient pod who fit the criteria. In addition, recruitment
posters will be postedat the following sites: Victoria Family Medical Centre, Lawson Health Research Institute,
St. Joseph's Hospital, Victoria Hospital, University Hospital, University of Western Ontario, Fanshawe College
and Brescia University College. These posters will contain the contact information of Roderick MacPhee {study
coordinator) so that potential participants may contact us directly. As well, the recruitment poster will be posted
on the Lawson Health Research Institute website of clinical trials. A message will also be placed in the LHSC ECast online newsletter which is available to hospital staff. Lastly, staff fromthe following clinics will be asked to
recruit eligible subjects fromtheir patient pool: Middlesex-London Health Unit, Byron Family Medical Centre and
St. Joseph's Family Medical Centre.

8.2a

8.3

What type of
consent will be or
was obtained from
participants?

No consent tobe obtained - Researcher requests waiver fromREB
Explicit written consent - use of formal consent documentation
Explicit verbal consent e.q telephone surveys
Explicit consent - other
eg completion ofquestionnaire, survey evidence of consent
Passive consent e.g, notices posted with option toopt out
Prior consent e g. prior research consent (append example copy)
Other (please describe)

If a w aiver to obtain prospective co nsent is being requested you must explain why.
As per the Ontario Personal Health Information Protection Act (PHIPA) requests towaive
consent are generally limited to the following reasons.
Investigators m ust indicatewhich are relevant and explain why.

X
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Inappropriateness o f c o nse nt requirem ent: There may be potential harms to individual
fromdirect contact e g. Psychological, social or other harmor distress could be caused by
contacting individuals or families.

= > n ia

8.3b

Inappropriateness o f c o nse nt requirem ent:

previous agreement, lawor policy.

Contact with individuals not permitted under a

=>n/a

8.3c

Im practicability

of seeking consent due io size and nature of population being studied.

= > n !a

83d
=*n/a
8.3e

Im practicability of seeking consent due toproportion of prospective participants likely to have
relocated or died since onginal data or specimen collection
Im practicability of seeking consent due to lack of existing or continuing relationship between
participants and data holder.

= *n/a

8.4

If a w a iv e r to obtain co n s e n t is being requested, what is the probability of harm related to retaining
the ability to identify data or specimens and theadequacy of security measures? If there are risks,
potential benefits tothe public and individuals must significantly outweigh potential harms to research
participants.
P R O B A B ILITY O F R IS K T O PA R TIC IP A N T AS A RESULT OF

High

A C C ES S IN G , USIN G O R D IS C LO S IN G TH E IR DATA O R

M oderate

M inim al
o r None

SPECIM ENS

8.4a
8.4b
8.4c
8 4d
8.4e
8.4f
8.4g

8.5a

85b

Physical injury
Emotional or psychological harm
Social harm (stigmatization, insurability, employability)
Financial harm
Intrusion on pnvacy
Loss of trust (e g, in institution or care givers etc.)
Other (specify)

In the case of previously collected or discarded biomaterials or specimens did
the donor consent to use for general research purposes?

YES
NO
DONT
If specimens are tobe collected prospectively indicate 'Not Applicable'
KNOW
Not
applicable X
If YES, prior explicit or implicit consent has already been obtained (e.g. for use of discarded or left over
specimens) please describe the nature of the consent (e g usual hospital surgical consent) and howif
was obtained and documented. If possble attach a sample of the document.________________
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IF YOU ARE ASKING FOR A WAIVER TO OBTAIN PROSPECTIVE CONSENT AND/OR HAVE PRIOR
CONSENT YOU HAVE NOWCOMPLETED THE FORM.
IF YOU WILL BE OBTAINING CONSENT OR NOTIFYING POTENTIAL PARTICIPANTS PLEASE
COMPLETE THE REST OF THE FORM.
Will posters, advertisements, public notices or telephone solicitation be used to
YES X
recruit or notify participants?
NO
8.6 b If YES attach copies of all posters, handouts, notices or advertisements etc. In the case of audio
announcements or telephone recruitment provide a written copy of thescript. If video or electronic
media are used e.g. video tape or CD’s provide only one ¡1) copy of tape or CD. This will be retained
by the Office of Research Ethics and will not be returned to the Investigator. Advert attached as
appendix A,
8.6a

8.7a
8.7b

8.8

Will minors or persons not able toconsent for themselves be included in the
YES
study?
NO
X
If YES, describe the consent process and indicate whowill be asked to consent on their behalf and
discuss what safeguards will be employed to ensure the rights of the research participant are
protected Whether or not a separate assent formis used, investigators and parents or guardians
should discuss the study with the person (when appropriate) and explain exactlywhat will happen and
what the persons rights are. In certain circumstances, the REB may find it acceptable for mature or
emancipated minors to give consent without also requiring consent fromparents or guardians.

Describe opportunities (if any) available toparticipants toconsent tofuture, as Not
yet unknown, research on their data or specimens. In the case of de-identified Applicable
data this is not an option, but researchers need to think carefully about the
logistics and likelihood of being able tocontact participants in the future if they
promise contact for future consent.

X

Describe what opportunities (if any) will be available toparticipants to withdraw Not
their data or specimens in the future.
Applicable

X

=>

89

Please note that it may be necessary todeny participants the right towithdraw
data or specimens toprotect the integrity of research already using the data. If
this is the case, this limitation on their ability towithdrawmust be made clear in
the Letter of Information.
In the case of de-identified data withdrawal is not an option.
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If YES, Attach a copy of all documentation that will be (or has been) used toinformand obtain consent
from Ihe potential participants about Ihe research. Separate Information/oonsent documents or a
combined InformationConsent document may be used. Wordng regarding the participant s consent
must comply with ihe UWO guidelines, be relevant tothe Canadian and Ontario scene and participants
must be given a copy of the Letter of Information or combined Informalion/consent document to keep
for reference. The letter of information and consent documentation included in this submission should
be on institutional letterheadand be presented as (hough it were the actual letter being given to
participants.
If announcements, posters or advertisements will be used toinformpotential participants that this
research is underway, attach a copy of all hardcopy advertisements /announcements/verbal scripts
etc that will be used
THE CHECKLIST ON NEXT PAGE IS DESIGNED TO ASSIST YOU IN THE PREPARATION OF THE
INFORMED CONSENT DOCUMENTATION WHEN USED INCONJUNCTION WITH THE
GUIDELINES FOR PREPARATION OF INFORMED CONSENT DOCUMENTATION IT WILL
ENSURE YOUR MATERIALS MEET THE REB's MINIMUMREQUIREMENTS.
C H EC K TH E D O C U M E N TS C A R E F U LLY FO R C O M P LE TE N E S S . IT IS THE IN V E STIG ATO R'S
R ES P O N S IB ILITY TO C O R R E C T A L L S P E LLIN G OR G R A M M A TIC A L ER RO RS AN D E N SUR E THE
D O C U M EN TS M EET U W O H S R E B S P E C IFIC A TIO N S

BEFORE SU B M ITTIN G THE P R O TO C O L TO

THE H SR EB. IN C O M PLETE O R POO RLY P R EPARE D C O N S E N T D O C UM E N TA TIO N IS A M AJO R
R EASO N W HY ETH IC S A P P R O V A L IS D E LAY ED.

See Guideline 2-G-005 (formerly Appendix 4) on the following website.
http://www.uwo.ca/research/ethics/med/hsreb-guidelines.htm

These are the contact persons for participants who have questions regarding their rights and theconduct of the
research. The correct person must be inserted into this sentence and this phrase included in the Letter of
Information.
“If you have any questions about your rights as a research participant or the conduct of the study you
may contact..."
If participants are recruited fromwithin
Dr. D avid Hill, Scientific D irector, Lawson Health R esearch Institute
Ihe LHSC or SJHC system or research is
taking place at LHSC or SJHC sites
If participants recruited fromsites other
than LHSC or SJHC and research not
The O ffice o f Research Ethics a t (519) 661-3036 or b y em ail at
taking place at LHSC or SJHC sites.
ethics@ uw o.ca.
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C H E C K L IS T -IN F O R M A T IO N & C O N S E N T D O C U M E N TA TIO N
To b e u s e d In c o n ju n c tio n w ith th e G u id e lin e s fo r p re p a ra tio n o f In fo rm a tio n & C o n s e n t

See 2-G-005 on the following website.
http://www.uwo.ca/research/ethics/med/hsreb-quidelines.htm
HAVE YOU INCLUDED OR ADDRESSED THE FOLLOWING ISSUES?
d o c u m e n ta tio n .

X
X

R eq u ire d
R equ ired
W hen appropriate

X
X
X
X
X
X
X

R equ ired
R equ ired
W hen appropriate
R equ ired
R equ ired
R equired
W hen ap propriate
W hen data goinq off-site

X

R equ ired

X

R equ ired
W hen appropriate

X
X
X
X
X

W hen appropriate
R equ ired
R equ ired
R equ ired
R equ ired
W hen appropriate

X
X
X
X
X

R equ ired
R eq u ire d
R equ ired
R equ ired
R eq u ire d

Title of the research
Identity of researchers &affiliation
Identity of sponsors if industry funded
Invitation toparticipate in research & complete description of what is
involved, including the time commitment and location
Provide summary explanation of research
Indicate number of participants - total &local
Describe Risks / Harms / Benefits - even if there are none
Voluntary participation, can refuse to participate, withdrawal of data etc
Discuss anonymity 8/or confidentiality of information
Explanation of compensation
Where data going, secunty measures, what will happen toit etc
Local contact person(s) for participants re questions about
database/registry/bank and/or treatment and care
Local contact person for participants re subiect riqhts
Access to records or follow up by HSREB to monitor the study
No waiver of riqhts
No indication of institutional approval
Statement that participant will receive copy of letter of information tokeep
Non identification in publication of results without specific consent
Consent Statement as per UWO standard
Consent options
Signatures of appropriate persons
Information/consent documents addressed to research participant
Language Level - lay language, grade 8 level for general population
No spelling or grammatical errors
Appropriately Formatted - on letterhead, pages numbered appropriate
type size, page layout, header/footer, headings etc
Consent Form Wording:

X

R equ ired
(W hen appropriate)

1have read the Letter of Information, (have had the nature of thestudy
explained tome) and 1agree toparticipate All questions have been
answered to my satisfaction.
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Appendix 2- Recruitment Poster

LAWSON
HEALTH RESEARCH INSTITUTE

Volunteers needed for study
to help prevent Toxic Shock
Syndrome

Females aged 18-40 with a history of bacterial vaginosis
are needed to provide samples at the Victoria Family
Medical Centre from which we hope to identify factors
involved in the development of toxic shock syndrome.
I f interested, or for more information, please contact:
Roderick MacPhee

Study Coordinator

Tel:i^

Email:!

You will be reimbursed for your time and travel expenses.
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Appendix 3- Letter of Information and Consent

P articipant ID #:

LAWSON

HEALTH RESEARCH INSTITUTE

Canadian Research & Development Centre for Probiotics
258 Gfosvenof Street. Room F2-116
London, Ontario NoA 4V2
CANADA

www.cidc-prowobcsca

The role of vaginal bacteria in toxic shock syndrome.
Investigator: Dr, Gregor Reid
Lawson Health Research Institute
The University of Western Ontario
London, Ontario
Purpose:

Researchers atthe Lawson Health Research Institute and Victoria Family Medical Centre,
Department of Family Medicine, University of Western Ontario, London, Ontario are presently
studying toxic shock syndrome in pre-menopausai women. The bacteria of the vaginal tract have
an impact upon the health status of women and may affect susceptibility toToxic Shot* Syndrome,
a condition that continues to affect many women. The presence of a condition known as Bacteria!
Vaginosis, in which the normal, good bacteria of the vagina have been depleted and replaced by
pathogenic bacteria, may also increase the risk of Toxic Shock Syndrome. The researchers will
use vaginal swab samples fromboth healthywomen and women diagnosed with Bacteria!
Vaginosis to look for indicators that decrease or increase the risk of productionof Toxic Shock
Syndrometoxin (TSST) by a harmful bacteriumcalled S taphylococcus aureus. The study is not
attempting to diagnose toxic shock syndrome in your sample - just using the sample todetermine
what happens when S taphylococcus a u reus is added totie swab contents inthe laboratory. This
study is being sponsored by Kimberly Clark Corporation (the sponsor), and as such,
representatives of Kimberly Clark will be provided with data obtained duringthe study.
Procedures:

If you agree to participate you will be asked to provide seven swab samples fromthe
vagina. Dr. Hammond or one oftie other doctors at the clinic will take the samples at Victoria
Family Medical Centre. The office visit will be approximately 15 minutes long. The samples will be
labelled with a numbering system that does not disclose your identity. The swabs collected during
the visit will be used to identifythe pH of the vaginal fluid for diagnostic purposes, to examinetoe
types of bacteria present intoe vagina at that time, and as a source of bacteria that will be
incubated with Staphylococcus a u m u s to lookfor changes in toxin production. Other swabs will be
used toextract DNA fromthe bacteria to examine the types of bacteria present in the vagina and
their effect upon the cells that line the vagina.

Initials:
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If you suffer any reactions (pain, discomfort, irritation or other signs or symptoms) that concern you
and dial you feel are due to the study, you should report these to Dr, Hammond, Upon enrolment in
the study, you will be given the opportunity to provide written consent for researchers to notify you
via your referring physician or family doctor should any clinical abnormality be detected fromthe
sample analysis.
Exclusion Criteria:

You should not participate in this study ifyou have any ofthe following: are pregnant;
recurrent sexually transmitted disease; abnormal renal function or pyelonephritis; are receiving
prednisone or immunosuppressive drugs; are receiving treatmentfor any urogenital infection or are
taking any antimicrobial therapy; have had a urogenital infection in the past 6 months; have a
personal history of known or suspected estrogen-dependent neoplasia such as breast or
endometrial cancer; have undiagnosed abnormal vaginal bleeding; have had a history of
gonorrhoea or chlamydia: have had sexual intercourse 48 hours before theclinical visit; have taken
any ‘acidophilus’ or probiotic health food supplements 48 hours beforethe clinical visit are
menstruating at time of clinical visit,
Contacts:

Participation in this study will not affect the treatmentof any medical problems you
experience. Should you have questions you should feel free to contact us:
Dr, J. Hammond
Referring Physician
Victoria Family Medical Centre
Or
Mr. Roderick MacPhee
Study Coordinator

If you have any questions about the conduct of this study or your rights as a research
subject, you may contact the Dr. David Hill, Scientific Director, Lawson Health Research Institute,

nitials:
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Risks:

We do notexpect that you will experience any risk by participating in this study. You may
experience some mild discomfort when the vaginal samples are collected, but this should not result
in any increased risk.
V olu ntary P articipation:

Participation in this study is voluntary. You may refuse to participate, or you may withdraw
fromthe study at any time with no effect on your future care.
C onfidentiality:

All information collected for the study will be kept confidential and will only be made
available to members of the research teamfor the purposes of data analysis. Participants will be
issued an identification number for sample submission. Your identity will only be known to your
referring physician and/or Dr. Hammond and will not be released tomembers ofthe research team
or sponsor. Data will be stored indefinitely on a password-protected computer in a locked
laboratory and all paper files will be kept in a locked filing cabinet in a locked office. All data will be
filed with sample identification numbers only—no names will be stored with the data. A copy of the
final data will be supplied tothe sponsor. If the results of the study are published, your name will
not be used and no information that discloses your identitywill be released or published.
Representatives ofThe University of Western Ontario Health Sciences Research Ethics Board may
contact you or require access to your study-related records to monitor the conduct of the research.
Benefits:

This study may help us better understand why some women develop toxic shock
syndrome and others do not The long-term goal is to reduce the risk of this condition through
interventions such as creams, probiotics, nutrients, or pads.
Consent:

By agreeing to participate in this study, you give your consent for the information given by
you and obtained fromyour samples can be compiled and analyzed with others participating in this
study. If you are participating in another study, please let us knowso that we can determine if you
should participate in this study.

Initials:
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Y our Rights:

You do notwaive any legal rights by signing the consent form.
C om pensation:

Each participantwill be compensated $50 for participation in the study to cover the cost of
parking and travel expenses tothe centre.
You will be provided with a photocopy ofthis letter.

Initials:
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The role of vaginal bacteria in toxic shock syndrome.
Consent
I,________________________ , have read the Letter of Information, have had die nature
of the study explained to me and I agree to participate. All questions have been answered to my
satisfaction,
I ___________ (DO or DO NOT) give my permission to contact my family physician should
any abnormality be identified during data analysis. If permission is granted, please supply name of
physician;
Name of Physician

Si gnature o f Particip an t

Date

N am e o f Particip an t (P lease Print)

Signature of person obtaining Informed Consent

Date

Name (Please Print)
Note:

the participant must initial each page of this letter and agreement.

Initials:_______
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Appendix 4- Study Questionnaire

LAWSON
Baseline Questionnaire
The role of vaginal bacteria in toxic shock syndrome.
Participant ID :________________

Date:___________

Instructions: The following questions are designed to assess the eligibility of the
participant based on the recruitment criteria for this study. Please answer as honestly
and clearly as possible.
F e e l fre e to a sk the stu d y co ord in a to r a b o u t a n y questions th a t m a y b e unclear.

1. Are you a female between the age of 18-40 years old?
Yes
Please S pe cify:______________

No
2. Have you reached menopause?
□ Yes
D No
3. Have you had any urogenital infections in the past 6 months? (This includes, but is
not limited to, sexually transmitted infections, bladder infections, yeast infections)
D Yes

Please Specify:_____________________
_____________________
_____________________

Date:____________
Date:____________
Date:____________

0 No

4. Are you pregnant?
D Yes
0 No
5. Have you had sex (oral or vaginal) within the past 48 hours?
0 Yes
D No

The research institute of Condon Health Sciences Centre and St. Joseph’s Health Care, Condon.
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6. Have you been diagnosed with gonorrhoea or chlamydia in the past?
0 Yes
No
7. Have you been diagnosed with abnormal renal function (including abnormal function of
or pyelonephritis (an ascending urinary tract infection)?
0 Yes
Please Specify:_____________
Date:__________
_____________
Date:__________
No

kidneys, ureters, biadder or urethra)

8. Are you currently receiving prednisone, immunosuppressive drugs or antimicrobial
medication?
0 Yes
D No
9. Do you have a history of estrogen-dependent neoplasia such as breast or
endometrial cancer?
D Yes
D No
10. Do you have any abnormal vaginal bleeding?
0 Yes
0 No
11. Have you taken probiotic supplements or foods in the past 48 hours?
0 Yes
D No
12. Are you currently menstruating at time of clinical visit?
Yes
C No

The research institute of London Health Sciences Centre and St. Joseph’s Health Care, London.
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Appendix 5A- Luminescence Data
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Appendix 5B- Growth Curves for Luminescence Assay
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Appendix 6- Growth Curves of S. aureus MN8 in Response to Supernatant
Challenge
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Appendix 7 - Publications During Thesis
7.1. Review of the most recent clinical trials studying the
effectiveness of probiotics for the treatment of bacterial vaginosis
MacPhee RA, Hummelen R, Bisanz JE, Miller WL, Reid G. Probiotic strategies for the
treatment and prevention of bacterial vaginosis. Expert Opin Pharmacother 2010;
11(18); 2985-95.
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7.2. Paper documenting the application of 16S rRNA sequencing
by illumina for studying vaginal samples
Gloor GB, Hummelen R, Macklaim JM, Dickson RJ, Fernandes AD, MacPhee R, Reid
G. Microbiome profiling by illumina sequencing of combinatorial sequence-tagged PCR
products. PLoS One 2010; 5(10): e15406.
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